EP1305324A1 - Use of chiral diphosphines as optically active ligands - Google Patents
Use of chiral diphosphines as optically active ligandsInfo
- Publication number
- EP1305324A1 EP1305324A1 EP01960868A EP01960868A EP1305324A1 EP 1305324 A1 EP1305324 A1 EP 1305324A1 EP 01960868 A EP01960868 A EP 01960868A EP 01960868 A EP01960868 A EP 01960868A EP 1305324 A1 EP1305324 A1 EP 1305324A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- group
- alkyl
- binap
- diphosphino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 48
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 6
- 229910052751 metal Inorganic materials 0.000 claims abstract description 5
- 239000002184 metal Substances 0.000 claims abstract description 5
- 238000005984 hydrogenation reaction Methods 0.000 claims abstract description 4
- 238000006317 isomerization reaction Methods 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- -1 sulfino, sulfonyl Chemical group 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000003054 catalyst Substances 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical group 0.000 claims description 16
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 claims description 15
- 239000000460 chlorine Substances 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 229910052710 silicon Inorganic materials 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 11
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 150000001450 anions Chemical class 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 7
- 101150065749 Churc1 gene Proteins 0.000 claims description 7
- 102100038239 Protein Churchill Human genes 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 229910052718 tin Inorganic materials 0.000 claims description 6
- 239000010936 titanium Substances 0.000 claims description 6
- 229910052719 titanium Inorganic materials 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 150000003512 tertiary amines Chemical class 0.000 claims description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- VYXHVRARDIDEHS-QGTKBVGQSA-N (1z,5z)-cycloocta-1,5-diene Chemical compound C\1C\C=C/CC\C=C/1 VYXHVRARDIDEHS-QGTKBVGQSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052703 rhodium Inorganic materials 0.000 claims description 2
- 239000010948 rhodium Substances 0.000 claims description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 9
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940086542 triethylamine Drugs 0.000 description 6
- 239000003480 eluent Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000012264 purified product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- XLSMFKSTNGKWQX-UHFFFAOYSA-N alpha-hydroxyacetone Natural products CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical compound C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NJBCRXCAPCODGX-UHFFFAOYSA-N 2-methyl-n-(2-methylpropyl)propan-1-amine Chemical compound CC(C)CNCC(C)C NJBCRXCAPCODGX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 150000004718 beta keto acids Chemical class 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- WFSOQEZHBFMIPW-UHFFFAOYSA-L cycloocta-1,3-diene;ruthenium(2+);dichloride Chemical compound [Cl-].[Cl-].[Ru+2].C1CCC=CC=CC1 WFSOQEZHBFMIPW-UHFFFAOYSA-L 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
- B01J31/2414—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5027—Polyphosphines
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/50—Redistribution or isomerisation reactions of C-C, C=C or C-C triple bonds
- B01J2231/52—Isomerisation reactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/60—Reduction reactions, e.g. hydrogenation
- B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
- B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
- B01J2231/643—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of R2C=O or R2C=NR (R= C, H)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/60—Reduction reactions, e.g. hydrogenation
- B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
- B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
- B01J2231/645—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
- B01J2531/0202—Polynuclearity
- B01J2531/0208—Bimetallic complexes, i.e. comprising one or more units of two metals, with metal-metal bonds but no all-metal (M)n rings, e.g. Cr2(OAc)4
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
- B01J2531/0261—Complexes comprising ligands with non-tetrahedral chirality
- B01J2531/0266—Axially chiral or atropisomeric ligands, e.g. bulky biaryls such as donor-substituted binaphthalenes, e.g. "BINAP" or "BINOL"
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/20—Complexes comprising metals of Group II (IIA or IIB) as the central metal
- B01J2531/26—Zinc
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/30—Complexes comprising metals of Group III (IIIA or IIIB) as the central metal
- B01J2531/31—Aluminium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/40—Complexes comprising metals of Group IV (IVA or IVB) as the central metal
- B01J2531/42—Tin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/40—Complexes comprising metals of Group IV (IVA or IVB) as the central metal
- B01J2531/46—Titanium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/821—Ruthenium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/822—Rhodium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/827—Iridium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the subject of the present invention is the use of irid diphosphines as optically active ligands for the preparation of diphosphino-metallic complexes.
- the invention also relates to diphosphino-metallic complexes comprising a chiral disphophin as a ligand and the asymmetric catalysis methods using these complexes.
- the invention more particularly contemplates the use of these diphosphino-metallic complexes in asymmetric hydrogenation or isomerization processes for the synthesis of organic products with desired chirality.
- the Applicant has now designed new diphosphino-metallic complexes comprising a chiral disphophine as an optically active ligand which are particularly useful for the synthesis of organic products with desired chirality with very high yields and enantioselectivity.
- the subject of the invention is therefore the use of a chiral diphosphine (R) or (S) of formula (I):
- R and Ri identical or different, represent a C 1 _ 10 alkyl group, saturated or unsaturated, a C 3 cycloalkyl group. 9 saturated or unsaturated, a C 5 _ 10 aryl group, said groups being optionally substituted by a halogen, a hydroxy, a C x 5 alkoxy, an amino such as NH 2 , NHR 4 , N (R 4 ) 2 , a sulfino, a sulfonyl, with R 4 representing an alkyl, an alkoxy or an alkylcarbonyl, said alkyl, cycloalkyl or aryl groups possibly comprising one or more heteroatoms such as 0, N, S, Si, or also R and Ri, together , represent a substituted or unsaturated C 2 _ 6 alkyl group, a saturated or unsaturated C 3 _ 9 cycloalkyl group, a C 5 _ 10 aryl group, said cycloalkyl or ary
- R2 and R3, identical or different, represent a C 3 cycloalkyl group. 8 saturated or no, an aryl eh C 6 _ 10 , said groups being optionally substituted by a halogen, a hydroxy, a C 1 _ 5 alkoxy, an amino such as NH 2 , NHR 4 , N (R 4 ) 2 , a sulfino, a sulfonyl, with R 4 representing an alkyl, an alkoxy or an alkylcarbonyl, said cycloalkyl or aryl groups optionally comprising one or more heteroatoms such as 0, N, S, Si, or also, R2 and R3 together form a carbocycle group at C 4 _ 8 saturated or not, a C 5 _ 10 aryl group, said groups being optionally substituted by a halogen, a hydroxy, a C x 5 alkoxy, an amino such as NH 2 , NHR 4 , N (R 4 ) 2
- the chiral diphosphines of formula (I) can be used according to the invention for the preparation of several types of diphosphino-metallic complexes.
- a first group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (II):
- M represents a metal such as ruthenium, rhodium or irridium
- X represents a halogen such as chlorine, bromine, fluorine or iodine
- Sv represents a tertiary amine, a ketone, an ether
- L represents a chiral diphosphine (R) or (S), of formula (I) above; y is an integer, 0 or 1; x is an integer, equal to 1 or 2; z is an integer, equal to 1 or 4; p is an integer, equal to 0 or 1.
- diphosphino-metallic complexes of formula (II) the invention more particularly contemplates the complexes of formulas (IIA) and (IIB).
- N (Et) 3 also designated Di [2, 2 '-bis (diphenylphosphino) (R) or (S) -6,6'- ditrimethylacetoxybiphenyl] -tetrachloro diruthenium triethylamine,
- a second group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (III):
- Ar represents an olefin such as ethylene, 1, 3-butadiene, cyclohexadiene, norbonadiene, cycloocta-1, 5-diene, a pi-allyl, a nitrile such as acetonitrile, an arene of formula ( IV):
- R5, R6, R7, R8, R9 and RIO are chosen from a hydrogen atom, a 1 alkyl group in 1 _ 5 , an isoalkyl group, a tertioalkyl group ⁇ , an alkoxy group, said groups comprising one or more heteroatoms such as 0, N and Si;
- Y represents an anion, such as C10 4 " , BF 4 " , PF 6 " ; j is an integer equal to 0 or 1; m is an integer equal to 1.2 or 4; n is an integer equal to 1 or 2.
- a third group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (V):
- M, X and L have the same definitions as in formula (II), and R 1X and R 12 , identical or different, represent a phenyl or a phenyl substituted by an alkyl, an alkoxy or a dialkylamino.
- a fourth group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (VI):
- M and L have the same meaning as in formula (II) and Z represents an acetate group of formula R 13 C00 ⁇ , diacetate of formula " OOCR 13 COO " , an aminoacetate of formula R 13 CH (NH 2 ) C00 ⁇ , wherein R 13 represents a C x _ 4 haloalkyl C x _ 4, a phenyl substituted or not.
- a fifth group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (VII):
- M, L and X have the same meaning as in formula (II); W represents zinc, aluminum, titanium or tin;
- a sixth group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (VIII):
- Y represents an anion, such as C10 4 _ , BF 4 " , PF 6 ⁇ .
- a seventh group of diphosphino-metallic complexes prepared using chiral diphosphines of formula (I) according to the invention corresponds to the following formula (IX):
- R2 and R3 have the same meanings as in formula (I).
- R2 and R3 have the same meanings as in formula (I).
- the complexes of formulas (VI) and (VII) can be obtained from the compounds of formulas (IIA) by analogy to the methods described in European patent applications No. 245 960 and No. 271 310.
- the complexes of Formulas (VIII), (IX) and (X) can be obtained from the compounds of formulas (IIB) by analogy to the methods described in European patent applications No. 256 634, No. 245 959 and No. 271 310.
- the present invention also relates to the diphosphino-metallic complexes of formulas (II), (III),
- the invention especially relates to their use in an asymmetric hydrogenation process of unsaturated compounds carrying functional groups of formula (XVI) below:
- a and B are different and chosen from a C 1 _ 5 alkyl group, an aryl group, a C x hydroxycarbonyl group, ⁇ , a C x _ ⁇ alkoxycarbonyl group, a C aryloxycarbonyl group. K ), a C ⁇ 7 halogenoalkyl group, a heteroaryl group, a saturated or unsaturated cycloalkyl group, said alkyl, aryl or cycloalkyl groups optionally comprising one or more substituents chosen from a halogen such as chlorine, fluorine, bromine, a -N0 2 group, an alkyl C x _ 5 alkoxy C x.
- a halogen such as chlorine, fluorine, bromine, a -N0 2 group, an alkyl C x _ 5 alkoxy C x.
- a C 1 _ 1 cycloalkyl fused or not a aryl group, fused or not, optionally substituted by a halogen, a C _ 5 alkyl, a C 1 _ 5 alkoxy, said alkyl, cycloalkyl or aryl groups comprising possibly one or more heteroatoms such as 0, N or Si,
- a and B together form a substituted C 2 _ 6 alkyl group, a C 3 _ 9 cycloalkyl group saturated or not, a C 5 _ 10 aryl group, said groups being optionally substituted by a C 1 _ alkyl 5 , halogen, hydroxy, C 5 alkoxy, amino such as NH 2 , NHR 4 , N (R 4 ) 2 , sulfino, sulfonyl, where R 4 represents alkyl, alkoxy or alkylcarbonyl , said alkyl, cycloalkyl or aryl groups optionally comprising one or more heteroatoms such as 0, N, S, Si;
- Q represents an oxygen, a group -NR16, -NOR16 or -C (R16) 2 , where R16 is chosen from alkyl C j. _ 5 , an aryl group, a heteroaryl group substituted by a C 1 _ 4 alkyl.
- non-limiting examples include the following compounds: ene-acid or ester derivatives, ene-alcohol or ether derivatives, ene-derivatives amide, e-amine derivatives, beta-ketoacid or ester derivatives, gam a-ketoacid or ester derivatives, beta, gamma-dicetoacid or ester derivatives, alpha-amido-beta derivatives cetoacid or ester, halogeno-ketone derivatives, hydroxy or alkoxy-ketone derivatives, i ine derivatives.
- a preferred asymmetric hydrogenation process comprises the treatment of a compound of formula (XVI), in an appropriate solvent, in the presence of a catalytic complex of formulas (II), (III), (V), (VI), (VII), (VIII), (IX) or (X), as a catalyst, under the operating conditions preferably as follows: - A temperature between 0 and +150 ° C.
- An amount of catalyst relative to the amount of substrate between 1/50000 and 1/10, preferably between 10/10000 and 1/10, most preferably 10/100 and 1/10.
- the hydrogenation time will generally be greater than or equal to 1 hour. Depending on the substrate and the catalyst, it may, for example, be between 1 hour and 70 hours.
- any solvent can be used, isolated or mixed, as long as it can dissolve the substrate and does not affect the reaction.
- a hydrocarbon such as hexane, heptane, octane, nonane, decane, benzene, toluene and xylene
- an ether such as tetrahydrofuran, tetrahydropyran, dioxane, dimethoxyethane, diisopropyl ether and diethylene glycol dimethyl ether
- an ester such as a formate or an alkyl acetate such as ethyl formate, ethyl acetate, butyl acetate and ethyl propionate
- a ketone such as acetone, diethylketone, diisopropylce t one, methylisobutylket one, methylethylketone and acetylace
- the substrate When carrying out the reaction, it is recommended to use the substrate at a concentration, in the solvent of 0.1 to 2 moles / liter.
- the reaction medium is concentrated.
- the residue is taken up with a solution of 220 ml of ethyl acetate and 50 ml of water.
- the reaction medium is left for 24 hours at 20 ° C, before hydrolysis.
- the expected product is obtained in the form of a brown oil.
- the product is obtained in the form of white crystals.
- the product is obtained in the form of white crystals.
- the product is obtained in the form of white or pale yellow crystals.
- the product is obtained in the form of white or pale yellow crystals.
- Example 10 Preparation of the catalyst: The complex [RuBr, (R) -CH 3 COOBIPHEP)],. acetone.
- Example 11 Preparation of the catalyst: The Ru (R) -CTCOOBIPHEP) (OAc) complex.
- Example 12 Preparation of the catalyst: The Ru (R) - (CHJ, CHCQOBIPHEP) (OAc) complex.
- Example 20 Asymmetric hydrogenation of ethylbenzoylacetate.
- Example 10 To the catalytic solution of Example 10, ethyl benzoylacetate (0.5 g; 0.0026 mol) and 5 ml of ethanol are added. One puts under a pressure of 20 bars of hydrogen. The medium is heated to 50 ° C. and left stirring for 22 hours.
- the medium is concentrated.
- Example 24 Asymmetric hydrogenation of the hydroxyacetone compound. Ligand A.
- Example 20 The same process is carried out as that of Example 20, taking into account the hydrogen pressure, the temperature and the substrate / catalyst ratio (S / C) indicated in the reaction.
- the expected product is obtained in the form of a brown liquid.
- Example 34 Asymmetric hydrogenation of the hydroxyacetone compound.
- Example 20 The same process is carried out as that of Example 20, taking into account the hydrogen pressure, the temperature and the substrate / catalyst ratio (S / C) indicated in the reaction.
- the expected product is obtained in the form of a brown liquid.
- Example 40 Asymmetric hydrogenation of the 4-chloroacetoacetate compound.
- Example 20 The same process is carried out as that of Example 20, taking into account the hydrogen pressure, the temperature and the substrate / catalyst ratio (S / C) indicated in the reaction.
- the expected product is obtained in the form of an oil.
- Example 42 Asymmetric hydrogenation of the compound Acetamide, N- [1- (2-naphtha ⁇ enyl) ethenyl].
- Example 20 The same process is carried out as that of Example 20, taking into account the hydrogen pressure, the temperature and the substrate / catalyst ratio (S / C) indicated in the reaction.
- the expected product is obtained in the form of an orange oil.
- Example 48 Asymmetric hydrogenation of the dimethyl Itaconate compound. Ligand A.
- the expected product is obtained in the form of a brown liquid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
The invention concerns the use of chiral diphosphines as optically active ligands for preparing diphosphino-metal complexes. The invention also concerns diphosphino-metal complexes comprising a chiral diphosphine as ligands and asymmetrical catalysis methods using said complexes. More particularly, the invention concerns the use of said diphosphino-metal complexes in asymmetrical hydrogenation or isomerization processes for the synthesis of organic products with desired chirality.
Description
UTILISATION DE DIPHOSPHINES CHIRALES COMME LIGANDS OPTIQUEMENT ACTIFS USE OF CHIRAL DIPHOSPHINES AS OPTICALLY ACTIVE LIGANDS
La présente invention a pour objet l'utilisation de diphosphines c irales comme ligands optiquement actifs pour la préparation de complexes diphosphino-métalliques. L'invention se rapporte aussi aux complexes diphosphino-métalliques comprenant une disphophine chirale comme ligand et les procédés de catalyse asymétriques mettant en œuvre ces complexes . L'invention envisage plus particulièrement l'utilisation de ces complexes diphosphino-métalliques dans des procédés d'hydrogénation ou d' isomerisation asymétrique pour la synthèse de produits organiques à chiralité voulue.The subject of the present invention is the use of irid diphosphines as optically active ligands for the preparation of diphosphino-metallic complexes. The invention also relates to diphosphino-metallic complexes comprising a chiral disphophin as a ligand and the asymmetric catalysis methods using these complexes. The invention more particularly contemplates the use of these diphosphino-metallic complexes in asymmetric hydrogenation or isomerization processes for the synthesis of organic products with desired chirality.
On connaît dans l'art antérieur, différents ligands utilisés pour la synthèse de complexes diphosphino- métalliques, ayant des propriétés catalytiques en hydrogénation assymétrique . On peut citer par exemple le composé BINAP décrit par la société Ta asago dans les demandes de brevet européen No. 444 930, No. 295 109, le composé MeOBIPHEP décrit par la société Hoffmann-La-Roche dans les demandes de brevet européen No. 398132 et PCT No.We know in the prior art, various ligands used for the synthesis of diphosphino-metallic complexes, having catalytic properties in asymmetric hydrogenation. We can cite for example the compound BINAP described by the company Ta asago in European patent applications No. 444 930, No. 295 109, the compound MeOBIPHEP described by the company Hoffmann-La-Roche in European patent applications No. 398132 and PCT No.
WO93/15090.WO93 / 15090.
La demanderesse a maintenant conçu de nouveaux complexes diphosphino-métalliques comprenant une disphophine chirale comme ligand optiquement actif tout particulièrement utiles pour la synthèse de produits organiques à chiralité voulue avec des rendements et une énantiosélectivité très élevés .
L ' invention a donc pour obj et l ' utilisation d ' une diphosphine chirale (R) ou ( S ) de formule ( I ) :The Applicant has now designed new diphosphino-metallic complexes comprising a chiral disphophine as an optically active ligand which are particularly useful for the synthesis of organic products with desired chirality with very high yields and enantioselectivity. The subject of the invention is therefore the use of a chiral diphosphine (R) or (S) of formula (I):
dans laquelle :in which :
R et Ri, identiques ou différents, représentent un groupement alkyle en C1_10 saturé ou non, un groupement cycloalkyle en C3.9 saturé ou non, un groupement aryle en C5_10, lesdits groupements étant éventuellement substitués par un halogène, un hydroxy, un alkoxy en Cx_5 , un amino tel que NH2 , NHR4 , N(R4)2, un sulfino, un sulfonyle, avec R4 représentant un alkyle, un alkoxy ou un alkylcarbonyle, lesdits groupements alkyle, cycloalkyle, aryle comprennant éventuellement un ou plusieurs hétéroatome tel que 0, N, S, Si, ou encore R et Ri, ensemble, représentent un groupement alkyle substitué en C2_6 saturé ou non, un groupement cycloalkyle en C3_9 saturé ou non, un groupement aryle en C5_10, lesdits groupements cycloalkyle ou aryle étant éventuellement substitués par un alkyle en C _5 , un halogène, un hydroxy, un alkoxy en Cx_5, un amino tel que NH2, NHR4, N(R4)2, un sulfino, un sulfonyle, avec R4 représentant un alkyle, un alkoxy ou un alkylcarbonyle, lesdits groupements alkyle, cycloalkyle, aryle comprennent éventuellement un ou plusieurs hétéroatome tel que 0, N, S, Si ;R and Ri, identical or different, represent a C 1 _ 10 alkyl group, saturated or unsaturated, a C 3 cycloalkyl group. 9 saturated or unsaturated, a C 5 _ 10 aryl group, said groups being optionally substituted by a halogen, a hydroxy, a C x 5 alkoxy, an amino such as NH 2 , NHR 4 , N (R 4 ) 2 , a sulfino, a sulfonyl, with R 4 representing an alkyl, an alkoxy or an alkylcarbonyl, said alkyl, cycloalkyl or aryl groups possibly comprising one or more heteroatoms such as 0, N, S, Si, or also R and Ri, together , represent a substituted or unsaturated C 2 _ 6 alkyl group, a saturated or unsaturated C 3 _ 9 cycloalkyl group, a C 5 _ 10 aryl group, said cycloalkyl or aryl groups being optionally substituted by a C _ alkyl 5 , halogen, hydroxy, C x 5 alkoxy, amino such as NH 2 , NHR 4 , N (R 4 ) 2 , sulfino, sulfonyl, with R 4 representing an alkyl, an alkoxy or a alkylcarbonyl, said alkyl, cycloalkyl or aryl groups optionally comprise one or more heteroatom e such that 0, N, S, Si;
R2 et R3 , identiques ou différents, représentent un groupement cycloalkyle en C3.8 saturé ou
non, un aryle eh C6_10, lesdits groupements étant éventuellement substitués par un halogène, un hydroxy, un alkoxy en C1_5 , un amino tel que NH2 , NHR4 , N(R4)2, un sulfino, un sulfonyle, avec R4 représentant un alkyle, un alkoxy ou un alkylcarbonyle, lesdits groupements cycloalkyle, aryle comprennant éventuellement un ou plusieurs hétéroatome tel que 0, N, S, Si, ou encore, R2 et R3 forment ensemble un groupement carbocycle en C4_8 saturé ou non , un groupement aryle en C5_10, lesdits groupements étant éventuellement substitués par un halogène, un hydroxy, un alkoxy en Cx_5 , un amino tel que NH2 , NHR4 , N(R4)2, un sulfino, un sulfonyle, avec R4 représentant un alkyle, un alkoxy ou un alkylcarbonyle, lesdits groupements carbocycle, aryle comprennant éventuellement un ou plusieurs hétéroatome tel que 0, N, S, Si ; comme ligand optiquement actif pour la préparation d'un complexe diphosphino-métallique.R2 and R3, identical or different, represent a C 3 cycloalkyl group. 8 saturated or no, an aryl eh C 6 _ 10 , said groups being optionally substituted by a halogen, a hydroxy, a C 1 _ 5 alkoxy, an amino such as NH 2 , NHR 4 , N (R 4 ) 2 , a sulfino, a sulfonyl, with R 4 representing an alkyl, an alkoxy or an alkylcarbonyl, said cycloalkyl or aryl groups optionally comprising one or more heteroatoms such as 0, N, S, Si, or also, R2 and R3 together form a carbocycle group at C 4 _ 8 saturated or not, a C 5 _ 10 aryl group, said groups being optionally substituted by a halogen, a hydroxy, a C x 5 alkoxy, an amino such as NH 2 , NHR 4 , N (R 4 ) 2 , a sulfino, a sulfonyl, with R 4 representing an alkyl, an alkoxy or an alkylcarbonyl, said carbocycle or aryl groups optionally comprising one or more heteroatoms such as 0, N, S, Si; as an optically active ligand for the preparation of a diphosphino-metallic complex.
Les diphosphines chirales de formule (I) peuvent être utilisées selon l'invention pour la préparation de plusieurs types de complexes diphosphino- métalliques .The chiral diphosphines of formula (I) can be used according to the invention for the preparation of several types of diphosphino-metallic complexes.
Un premier groupe de complexes diphosphino- métalliques préparés en utilisant les diphosphines chirales de formule (I) selon l'invention répond à la formule (II) suivante :A first group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (II):
MxEyKz ( ) 2 (Sv)p (II) dans laquelle, M représente un métal tel que le ruthénium, le rhodium ou 1 ' irridium ;M x E y K z () 2 (Sv) p (II) in which, M represents a metal such as ruthenium, rhodium or irridium;
X représente un halogène tel que le chlore, le brome, le fluor ou l'iode ;
Sv représente une aminé tertiaire, une cétone, un éther ;X represents a halogen such as chlorine, bromine, fluorine or iodine; Sv represents a tertiary amine, a ketone, an ether;
L représente une diphosphine chirale (R) ou (S) , de formule (I) ci-dessus ; y est un nombre entier, égale à 0 ou 1 ; x est un nombre entier, égale à 1 ou 2 ; z est un nombre entier, égale à 1 ou 4 ; p est un nombre entier, égale à 0 ou 1 .L represents a chiral diphosphine (R) or (S), of formula (I) above; y is an integer, 0 or 1; x is an integer, equal to 1 or 2; z is an integer, equal to 1 or 4; p is an integer, equal to 0 or 1.
Parmi les complexes diphosphino-métalliques de formule (II), l'invention envisage plus particulièrement les complexes de formules (IIA) et (IIB) .Among the diphosphino-metallic complexes of formula (II), the invention more particularly contemplates the complexes of formulas (IIA) and (IIB).
Les complexes de formule (IIA) sont ceux où y=0 et alors x=2 , z = 4 et p=l, ces complexes répondent à la formule (IIA) suivante : M2X4L2 (Sv) (IIA) dans laquelle M, X, L et Sv ont la même signification que dans la formule (II) .The complexes of formula (IIA) are those where y = 0 and then x = 2, z = 4 and p = l, these complexes correspond to the following formula (IIA): M 2 X 4 L 2 (Sv) (IIA) in which M, X, L and Sv have the same meaning as in formula (II).
A titre d'exemples de complexes de formule (IIA) , on peut citer : - Ru4Cl2[(R) ou (S) CH3C00-Binap] 2. N(Et)3 , aussi désigné Di [2 , 2 ' -bis (diphenylphosphino) (R) ou (S)- 6, 6' -diacé t oxybiphenyl ] -tetrachloro diruthénium triethy lamine ,As examples of complexes of formula (IIA), there may be mentioned: - Ru 4 Cl 2 [(R) or (S) CH 3 C00-Binap] 2 . N (Et) 3 , also designated Di [2, 2 '-bis (diphenylphosphino) (R) or (S) - 6, 6' - diacé t oxybiphenyl] -tetrachloro diruthenium triethy lamine,
- Ru4Cl2 ( (Me) 2CHCOO-Binap) 2. N(Et)3 , aussi désigné Di [2 , 2 ' -bis (diphenylphosphino) (R) ou (S)-6,6'-di- i s obutanoyl oxybiphenyl ] -tetrachloro diruthénium triethylamine ,- Ru 4 Cl 2 ((Me) 2 CHCOO-Binap) 2 . N (Et) 3 , also designated Di [2, 2 '-bis (diphenylphosphino) (R) or (S) -6,6'-di- is obutanoyl oxybiphenyl] -tetrachloro diruthenium triethylamine,
- Ru4Cl2 ( (CH3)3CCOO-Binap) 2. N(Et)3 , aussi désigné Di [2 , 2 ' -bis (diphenylphosphino) (R) ou (S)-6,6'- ditrimethylacetoxybiphenyl ] -tetrachloro diruthénium triethylamine ,- Ru 4 Cl 2 ((CH 3 ) 3 CCOO-Binap) 2 . N (Et) 3 , also designated Di [2, 2 '-bis (diphenylphosphino) (R) or (S) -6,6'- ditrimethylacetoxybiphenyl] -tetrachloro diruthenium triethylamine,
- Ru4Cl2( (Me)2CHCH2COO-Binap)2. N(Et)3,- Ru 4 Cl 2 ((Me) 2 CHCH 2 COO-Binap) 2 . N (And) 3 ,
- Ru4Cl2 (CH3COO-Binap)2. C0(Me)2,- Ru 4 Cl 2 (CH 3 COO-Binap) 2 . C0 (Me) 2 ,
- Ru4Br2(CH3COO-Binap)2. N(Et)3,
- Ru4Br2( (Me)2CHCOO-Binap)2. N(Et)3,- Ru 4 Br 2 (CH 3 COO-Binap) 2 . N (And) 3 , - Ru 4 Br 2 ((Me) 2 CHCOO-Binap) 2 . N (And) 3 ,
- Ru4Br2( (CH3)3CCOO-Binap)2. N(Et)3,- Ru 4 Br 2 ((CH 3 ) 3 CCOO-Binap) 2 . N (And) 3 ,
- Ru4Br2( (Me)2CHCH2COO-Binap)2. N(Et)3,- Ru 4 Br 2 ((Me) 2 CHCH 2 COO-Binap) 2 . N (And) 3 ,
- Ru4Br2(CH3COO-Binap)2. CO(Me)2, - Ru4Br2( (Me)2CHCOO-Binap)2. CO(Me)2,- Ru 4 Br 2 (CH 3 COO-Binap) 2 . CO (Me) 2 , - Ru 4 Br 2 ((Me) 2 CHCOO-Binap) 2 . CO (Me) 2 ,
- Ru4Br2( (CH3)3CCOO-Binap)2. CO(Me)2,- Ru 4 Br 2 ((CH 3 ) 3 CCOO-Binap) 2 . CO (Me) 2 ,
- Ru4Br2 ( (Me ) 2CHCH2COO-Binap ) 2. CO (Me ) 2 ,- Ru 4 Br 2 ((Me) 2 CHCH 2 COO-Binap) 2 . CO (Me) 2 ,
- Ru4Br2 (C6H5COO-Binap)2. CO(Me)2,- Ru 4 Br 2 (C 6 H 5 COO-Binap) 2 . CO (Me) 2 ,
- Ru4Br2 (CsH11COO-Binap)2- CO(Me)2, - Ru4Br2 (C4H3OCOO-Binap)2. CO(Me)2,- Ru 4 Br 2 (C s H 11 COO-Binap) 2 - CO (Me) 2 , - Ru 4 Br 2 (C 4 H 3 OCOO-Binap) 2 . CO (Me) 2 ,
- Ru4Br2 (CH3OCH2COO-Binap)2. CO(Me)2.- Ru 4 Br 2 (CH 3 OCH 2 COO-Binap) 2 . CO (Me) 2 .
Les composés de formule (IIB) sont ceux où y=l alors x=l, z=l et p=0, ces complexes répondent à la formule (IIB) suivante : MHXL2 (IIB) dans laquelle M, X et L ont la même signification que dans la formule (II) et H représente un atome d'hydrogène.The compounds of formula (IIB) are those where y = l then x = l, z = l and p = 0, these complexes correspond to the following formula (IIB): MHXL 2 (IIB) in which M, X and L have the same meaning as in formula (II) and H represents a hydrogen atom.
Un deuxième groupe de complexes diphosphino- métalliques préparés en utilisant les diphosphines chirales de formule (I) selon l'invention répond à la formule (III) suivante :A second group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (III):
MXd(Ar)mLYn (III) dans laquelle, M, X, L ont la même signification que dans la formule (II) ;MX d (Ar) m LY n (III) in which, M, X, L have the same meaning as in formula (II);
Ar représente une oléfine telle que l'éthylène, le 1, 3-butadiène, le cyclohexadiène, le norbonadiène, le cycloocta-1 , 5-diène , un pi-allyle, un nitrile tel que 1 ' acetonitrile, un arène de formule (IV) :Ar represents an olefin such as ethylene, 1, 3-butadiene, cyclohexadiene, norbonadiene, cycloocta-1, 5-diene, a pi-allyl, a nitrile such as acetonitrile, an arene of formula ( IV):
où R5 , R6, R7 , R8 , R9 et RIO, identiques ou différents, sont choisis parmi un atome d'hydrogène, un1 groupement alkyle en 1_5 , un groupement isoalkyle, un groupement tertioalkyl^, un groupement alkoxy, lesdits groupements comprenant un ou plusieurs heteroatomes comme 0, N et Si ; where R5, R6, R7, R8, R9 and RIO, identical or different, are chosen from a hydrogen atom, a 1 alkyl group in 1 _ 5 , an isoalkyl group, a tertioalkyl group ^, an alkoxy group, said groups comprising one or more heteroatoms such as 0, N and Si;
Y représente un anion, tel que C104 ", BF4 ", PF6 " ; j est un nombre entier égale à 0 ou 1 ; m est un nombre entier égale à 1,2 ou 4 ; n est un nombre entier égale à 1 ou 2.Y represents an anion, such as C10 4 " , BF 4 " , PF 6 " ; j is an integer equal to 0 or 1; m is an integer equal to 1.2 or 4; n is an integer equal to 1 or 2.
Un troisième groupe de complexes diphosphino- métalliques préparés en utilisant les diphosphines chirales de formule (I) selon l'invention répond à la formule (V) suivante :A third group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (V):
[MX(P(R11)2(R12) )L]2 X (V) dans laquelle[MX (P (R 11 ) 2 (R 12 )) L] 2 X (V) in which
M, X et L ont les mêmes définitions que dans la formule (II), et R1X et R12, identiques ou différents, représentent un phényle ou un phényle substitué par un alkyle, un alkoxy ou un dialkylamino .M, X and L have the same definitions as in formula (II), and R 1X and R 12 , identical or different, represent a phenyl or a phenyl substituted by an alkyl, an alkoxy or a dialkylamino.
Un quatrième groupe de complexes diphosphino- métalliques préparés en utilisant les diphosphines chirales de formule (I) selon l'invention répond à la formule (VI) suivante :A fourth group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (VI):
M(L)Z2 (VI) dans laquelle,M (L) Z 2 (VI) in which,
M et L ont la même signification que dans la formule (II) et Z représente un groupement acétate de formule R13C00~, diacetate de formule "OOCR13COO", un aminoacetate de formule R13CH (NH2) C00~, où R13 représente un alkyle en Cx_4, un halogénoalkyle en Cx_4 , un phényle substitué ou non.
Un cinquième groupe de complexes diphosphino- métalliques préparés en utilisant les diphosphines chirales de formule (I) selon l'invention répond à la formule (VII) suivante :M and L have the same meaning as in formula (II) and Z represents an acetate group of formula R 13 C00 ~ , diacetate of formula " OOCR 13 COO " , an aminoacetate of formula R 13 CH (NH 2 ) C00 ~ , wherein R 13 represents a C x _ 4 haloalkyl C x _ 4, a phenyl substituted or not. A fifth group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (VII):
[M(L)WXk]n Z'p (VII) dans laquelle :[M (L) WX k ] n Z ' p (VII) in which:
M, L et X ont la même signification que dans la formule (II) ; W représente du zinc, de l'aluminium, du titane ou de 1 ' étain ;M, L and X have the same meaning as in formula (II); W represents zinc, aluminum, titanium or tin;
Z ' représente :Z 'represents:
- soit un groupement acétate de formule R14C00" où R14 représente un alkyle en C-^, un halogénoalkyle C1_4, un phényle substitué ou non, et dans ce cas n=l et p=2 , et lorsque W est Zn alors k=2, lorsque W est Al alors k=-3 , et lorsque W est Ti ou Sn alors k=4, soit une aminé tertiaire, comme la triethylamine, et dans ce cas n=2 et p=l, et lorsque W est Zn alors k=4, lorsque W est Al alors k=-5 et lorque W est Ti ou Sn alors k -6 .- Or an acetate group of formula R 14 C00 " where R 14 represents a C 1 ^ alkyl, a C 1 _ 4 haloalkyl, a substituted or unsubstituted phenyl, and in this case n = 1 and p = 2, and when W is Zn then k = 2, when W is Al then k = -3, and when W is Ti or Sn then k = 4, or a tertiary amine, such as triethylamine, and in this case n = 2 and p = l, and when W is Zn then k = 4, when W is Al then k = -5 and when W is Ti or Sn then k -6.
Un sixième groupe de complexes diphosphino- métalliques préparés en utilisant les diphosphines chirales de formule (I) selon l'invention répond à la formule (VIII) suivante :A sixth group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (VIII):
MH(L)2Y (VIII) dans l aque l l e H r epré s en t e un a t ome d ' hydrogène , M et L ont la même signif ication que dans la formule ( II ) ;MH (L) 2 Y (VIII) in which the H expresses a atom of hydrogen, M and L have the same meaning as in formula (II);
Y représente un anion , tel que C104 _ , BF4 " , PF6 ~ .Y represents an anion, such as C10 4 _ , BF 4 " , PF 6 ~ .
Un septième groupe de complexes diphosphino- métalliques préparés en utilisant les diphosphines chirales
de formule (I) selon l'invention répond à la formule (IX) suivante :A seventh group of diphosphino-metallic complexes prepared using chiral diphosphines of formula (I) according to the invention corresponds to the following formula (IX):
M(L)Y2 (IX) dans laquelle M et L ont la même signification que dans la formule (II) et Y représente un anion, tel queM (L) Y 2 (IX) in which M and L have the same meaning as in formula (II) and Y represents an anion, such that
CIO BP_ PF,CIO BP_ PF,
Un huitième groupe de complexes diphosphino- métalliques préparés en utilisant les diphosphines chirales de formule (I) selon l'invention répond à la formule (X) suivante :An eighth group of diphosphino-metallic complexes prepared using the chiral diphosphines of formula (I) according to the invention corresponds to the following formula (X):
M(L)2Y (X) dans laquelle M et L ont la même signification que dans la formule (II) et Y représente un anion, tel que C104-, BF4 ", PF6 ~.M (L) 2 Y (X) in which M and L have the same meaning as in formula (II) and Y represents an anion, such as C10 4 -, BF 4 " , PF 6 ~ .
Les diphosphines chirales (R) ou (S) de formule (I) peuvent être préparées par des procédés bien connus de l'homme du métier à partir de composés de formule (XI) :The chiral diphosphines (R) or (S) of formula (I) can be prepared by methods well known to those skilled in the art from compounds of formula (XI):
dans laquelle, R2 et R3 ont les mêmes significations que dans la formule (I) .in which, R2 and R3 have the same meanings as in formula (I).
Ces procédés consiste à mettre en présence un composé de formule (XI) et un composé dérivé d'un halogénure d'acide de formule RCOX ou R1COX, où R et Ri ont la même signification que dans la formule (I) et X ayant la même signification que- dans la formule (II) .
Le composé de formule (XI) est préparé, selon le procédé décrit dans la demande de brevet PCT No. WO9315090, à partir du composé de formule (XII) :These methods consist in bringing together a compound of formula (XI) and a compound derived from an acid halide of formula RCOX or R1COX, where R and Ri have the same meaning as in formula (I) and X having the same meaning as in formula (II). The compound of formula (XI) is prepared, according to the method described in PCT patent application No. WO9315090, from the compound of formula (XII):
dans laquelle , R2 et R3 ont les mêmes significations que dans la formule ( I ) . in which, R2 and R3 have the same meanings as in formula (I).
Les complexes de formules (II) , (III) et (V) peuvent être préparés par analogie selon des méthodes décrites dans l'art antérieur.The complexes of formulas (II), (III) and (V) can be prepared by analogy according to methods described in the prior art.
En effet, selon le procédé décrit dans la demande de brevet européen No. 174 057, les complexes de formules (II) peuvent être préparés à partir d'un composé de formule (XIII) :Indeed, according to the process described in European patent application No. 174 057, the complexes of formulas (II) can be prepared from a compound of formula (XIII):
MX2(C0D)2 (XIII) dans laquelle M, X ont les mêmes significations que dans la formule (II) et COD représente le cyclooctadiène.MX 2 (C0D) 2 (XIII) in which M, X have the same meanings as in formula (II) and COD represents cyclooctadiene.
De même, selon le procédé décrit dans la demande de brevet européen No. 366 390, les complexes de formules (III) peuvent être préparés à partir d'un composé de formule (XIV) :Likewise, according to the process described in European patent application No. 366 390, the complexes of formulas (III) can be prepared from a compound of formula (XIV):
[MX2(Ar)]2 (XIV) dans laquelle M, X et Ar ont les mêmes significations que dans la formule (III) .[MX 2 (Ar)] 2 (XIV) in which M, X and Ar have the same meanings as in formula (III).
Enfin, selon le procédé décrit dans la demande de brevet européen No. 470 756, les composés de formules
(V) peuvent être préparés à partir d'un composé de formule (XV) :Finally, according to the process described in European patent application No. 470 756, the compounds of formulas (V) can be prepared from a compound of formula (XV):
[MX(P(R11)2(R12) ) (DMA) ]2 X (XV) dans laquelle M, X , Rll et R12 ont les mêmes définitions que dans la formule (V) et DMA représente le diméthylacetamide .[MX (P (R11) 2 (R12)) (DMA)] 2 X (XV) in which M, X, R11 and R12 have the same definitions as in formula (V) and DMA represents dimethylacetamide.
Les complexes de formules (VI) , (VII) , (VIII) , (IX) et (X) peuvent être également préparés par analogie selon des méthodes décrites dans l'art antérieur.The complexes of formulas (VI), (VII), (VIII), (IX) and (X) can also be prepared by analogy according to methods described in the prior art.
En effet, les complexes de formules (VI) et (VII) peuvent être obtenus à partir des composés de formules (IIA) par analogie des procédés décrits dans les demandes de brevet européen No. 245 960 et No. 271 310. Les complexes de formules (VIII), (IX) et (X) peuvent être obtenus à partir des composés de formules (IIB) par analogie des procédés décrits dans les demandes de brevet européen No. 256 634, No. 245 959 et No. 271 310.In fact, the complexes of formulas (VI) and (VII) can be obtained from the compounds of formulas (IIA) by analogy to the methods described in European patent applications No. 245 960 and No. 271 310. The complexes of Formulas (VIII), (IX) and (X) can be obtained from the compounds of formulas (IIB) by analogy to the methods described in European patent applications No. 256 634, No. 245 959 and No. 271 310.
La présente invention concerne également les complexes diphosphino-métalliques de formules (II) , (III) ,The present invention also relates to the diphosphino-metallic complexes of formulas (II), (III),
(V) , (VI) , (VII) , (VIII) , (IX) et (X) , ainsi que leur utilisation comme catalyseur dans des procédés de catalyse asymétrique. Ainsi, l'invention envisage plus particulièrement leur utilisation dans des procédés d'hydrogénation asymétrique ou d' isomerisation asymétrique.(V), (VI), (VII), (VIII), (IX) and (X), as well as their use as a catalyst in asymmetric catalysis processes. Thus, the invention more particularly contemplates their use in asymmetric hydrogenation or asymmetric isomerization processes.
L'invention concerne tout spécialement leur utilisation dans un procédé d'hydrogénation asymétrique de composés insaturés porteurs de groupements fonctionnels de formule (XVI) suivante :
The invention especially relates to their use in an asymmetric hydrogenation process of unsaturated compounds carrying functional groups of formula (XVI) below:
dans laquelle :in which :
A et B, sont différents et choisis parmi un groupement alkyle en C1_5 , un groupement aryle, un groupement hydroxycarbonyle en Cx,η , un groupement alkoxycarbonyle en Cx_η , un groupement aryloxycarbonyle en C.-.K), un groupement halogenoalkyle en C±_7 , un groupement hétéroaryle, un groupement cycloalkyle saturé ou non, Lesdits groupements Alkyle, aryle, cycloalkyle comprenant éventuellement un ou plusieurs substituants choisis parmi un halogène comme le chlore, le fluor, le brome, un groupe -N02, un alkyl en Cx_5 , un alkoxy en Cx.5 , un cycloalkyle en C1_1 fusionné ou non , un groupe aryle, fusionné ou non, éventuellement substitué par un halogène, un alkyl en C _5 , un alkoxy en C1_5 , lesdits groupements alkyle, cycloalkyl, aryl comprenant éventuellement un ou plusieurs heteroatomes tels que 0, N ou Si,A and B are different and chosen from a C 1 _ 5 alkyl group, an aryl group, a C x hydroxycarbonyl group, η , a C x _ η alkoxycarbonyl group, a C aryloxycarbonyl group. K ), a C ± 7 halogenoalkyl group, a heteroaryl group, a saturated or unsaturated cycloalkyl group, said alkyl, aryl or cycloalkyl groups optionally comprising one or more substituents chosen from a halogen such as chlorine, fluorine, bromine, a -N0 2 group, an alkyl C x _ 5 alkoxy C x. 5 , a C 1 _ 1 cycloalkyl fused or not, a aryl group, fused or not, optionally substituted by a halogen, a C _ 5 alkyl, a C 1 _ 5 alkoxy, said alkyl, cycloalkyl or aryl groups comprising possibly one or more heteroatoms such as 0, N or Si,
Ou encore A et B forment ensemble un groupement alkyle substitué en C2_6, un groupement cycloalkyle en C3_9 saturé ou non, un groupement aryle en C5_10, lesdits groupements étant éventuellement substitués par un alkyle en C1_5 , un halogène, un hydroxy, un alkoxy en C _5 , un amino tel que NH2 , NHR4, N(R4)2, un sulfino, un sulfonyle, où R4 représente un alkyle, un alkoxy ou un alkylcarbonyle, lesdits groupements alkyle, cycloalkyle, aryle comprennant éventuellement un ou plusieurs heteroatomes tels que 0, N, S, Si ;Or A and B together form a substituted C 2 _ 6 alkyl group, a C 3 _ 9 cycloalkyl group saturated or not, a C 5 _ 10 aryl group, said groups being optionally substituted by a C 1 _ alkyl 5 , halogen, hydroxy, C 5 alkoxy, amino such as NH 2 , NHR 4 , N (R 4 ) 2 , sulfino, sulfonyl, where R 4 represents alkyl, alkoxy or alkylcarbonyl , said alkyl, cycloalkyl or aryl groups optionally comprising one or more heteroatoms such as 0, N, S, Si;
Q représente un oxygène, un groupe -NR16, -N0R16 ou -C(R16)2, où R16 est choisi parmi un alkyl en
Cj._5, un groupement aryl , un groupement hétéroaryle substitué par un alkyle en C1_4.Q represents an oxygen, a group -NR16, -NOR16 or -C (R16) 2 , where R16 is chosen from alkyl C j. _ 5 , an aryl group, a heteroaryl group substituted by a C 1 _ 4 alkyl.
Parmi les composés de formules (XVI) , on peut citer à titre d'exemples non limitatifs, les composés suivants : les dérivés d'ene-acide ou ester, les dérivés d'ene-alcool ou ether, les dérivés d'ene-amide, les dérivés d'ene-amine, les dérivés de bêta-cetoacide ou ester, les dérivés de gam a-cetoacide ou ester, les dérivés de bêta, gamma-dicetoacide ou ester, les dérivés d' alpha-amido-bêta- cetoacide ou ester, les dérivés d'halogeno-cetone, les dérivés d'hydroxy ou alkoxy-cetone, les dérivés d'i ine.Among the compounds of formulas (XVI), non-limiting examples that may be mentioned include the following compounds: ene-acid or ester derivatives, ene-alcohol or ether derivatives, ene-derivatives amide, e-amine derivatives, beta-ketoacid or ester derivatives, gam a-ketoacid or ester derivatives, beta, gamma-dicetoacid or ester derivatives, alpha-amido-beta derivatives cetoacid or ester, halogeno-ketone derivatives, hydroxy or alkoxy-ketone derivatives, i ine derivatives.
Un procédé d'hydrogénation asymétrique préféré selon l'invention comprend le traitement d'un composé de formule (XVI) , dans un solvant approprié, en présence d'un complexe catalytique de formules (II), (III), (V), (VI), (VII) , (VIII) , (IX) ou (X) , en tant que catalyseur, dans les conditions opératoires préférentiellement les suivantes : - Une température comprise entre 0 et +150 °C.A preferred asymmetric hydrogenation process according to the invention comprises the treatment of a compound of formula (XVI), in an appropriate solvent, in the presence of a catalytic complex of formulas (II), (III), (V), (VI), (VII), (VIII), (IX) or (X), as a catalyst, under the operating conditions preferably as follows: - A temperature between 0 and +150 ° C.
- Une pression d'hydrogène entre 1 et 20 bars ou entre 1 et 100 bars.- A hydrogen pressure between 1 and 20 bars or between 1 and 100 bars.
- Une quantité de catalyseur par rapport à la quantité de substrat comprise entre 1/50000 et 1/10, de préférence comprise 10/10000 et 1/10, tout préférentiellement 10/100 et 1/10.- An amount of catalyst relative to the amount of substrate between 1/50000 and 1/10, preferably between 10/10000 and 1/10, most preferably 10/100 and 1/10.
La durée d'hydrogénation sera en général supérieure ou égale à 1 heure. En fonction du substrat et du catalyseur, elle pourra, par exemple, être comprise entre 1 heure et 70 heures.The hydrogenation time will generally be greater than or equal to 1 hour. Depending on the substrate and the catalyst, it may, for example, be between 1 hour and 70 hours.
Tout solvant peut être utilisé, isolé ou en mélange, pour autant qu'il puisse dissoudre le substrat et n'affecte pas la réaction. Parmi les solvants susceptibles d'être utilisés dans le procédé ci-dessus, on peut citer
l'eau, un hydrocarbure comme l'hexane, l'heptane, l'octane, le nonane, le décane, le benzène, le toluène et le xylène, un ether comme le tetrahydrofurane, le tetrahydropyrane, le dioxane, le dimethoxyethane, le diisopropyl éther et le diethylène glycol dimethyl éther, un ester comme un formate ou un acétate d' alkyle comme le formate d'éthyle, l'acétate d'éthyle, l'acétate de butyle et le propionate d'éthyle, une cétone comme l'acétone, le diéthylcétone , le diisopropylce t one , le methylisobutylcét one , le methylethylcetone et 1 ' acetylacetone, un alcool comme le methanol, l'ethanol, le n-propanol et 1 ' iso-propanol , un nitrile comme 1 ' acétonitrile, un halogénure d' alkyle comme le dichlorométhane , le chloroforme et le 1,2- dichloroethane, une aminé comme la diméthylamine , la triethylamine, le diisobutylamine, la triethylamine, la N- methylpipéridine , 1 ' ethyldiisopropylamine , la N- methylcyclohexylamine et la pyridine, un acide organique comme l'acide acétique, l'acide propionique et l'acide formique, un a ide comme la dimethylformamide et la N- méthylformamide.Any solvent can be used, isolated or mixed, as long as it can dissolve the substrate and does not affect the reaction. Among the solvents which may be used in the above process, mention may be made of water, a hydrocarbon such as hexane, heptane, octane, nonane, decane, benzene, toluene and xylene, an ether such as tetrahydrofuran, tetrahydropyran, dioxane, dimethoxyethane, diisopropyl ether and diethylene glycol dimethyl ether, an ester such as a formate or an alkyl acetate such as ethyl formate, ethyl acetate, butyl acetate and ethyl propionate, a ketone such as acetone, diethylketone, diisopropylce t one, methylisobutylket one, methylethylketone and acetylacetone, an alcohol such as methanol, ethanol, n-propanol and 1 isopropanol, a nitrile such as acetonitrile, an alkyl halide such as dichloromethane, chloroform and 1,2-dichloroethane, an amine such as dimethylamine, triethylamine, diisobutylamine, triethylamine, N-methylpiperidine, ethyldiisopropylamine, N-methylcyclohexylamine and pyridine , an organic acid like ac ide acetic, propionic acid and formic acid, an ide like dimethylformamide and N-methylformamide.
Lors de la mise en œuvre de la réaction, on recommande d'utiliser le substrat à une concentration, dans le solvant de 0,1 à 2 moles/litre.When carrying out the reaction, it is recommended to use the substrate at a concentration, in the solvent of 0.1 to 2 moles / liter.
D'autres avantages et caractéristiques de l'invention apparaîtront dans les exemples qui suivent donnés à titre non limitatif.Other advantages and characteristics of the invention will appear in the examples which follow, given without implied limitation.
I - Préparation des ligands .I - Preparation of ligands.
Exemple 1 : Préparation du ligand (R) -HOBIPHEP : (R) -6, 6' -Dihydroxybiphenyl-2 , 2 ' -diyl bis (diphenylphosphine) .Example 1: Preparation of the ligand (R) -HOBIPHEP: (R) -6, 6 '-Dihydroxybiphenyl-2, 2' -diyl bis (diphenylphosphine).
On applique le procédé décrit dans la demande de brevet PCT No. WO9315090.
Le composé (R) -HOBIPHEP est ' '.obtenu avec un rendement quantitatif.The method described in PCT patent application No. WO9315090 is applied. The compound (R) -HOBIPHEP is ''. Obtained with a quantitative yield.
Exemple 2 : Préparation .du ligand (R)- CH2COOBIPHEP (Abrégé A) : (R) -6 , 6 ' -acetoxybiphenyl-2 , 2 ' - diyl bis (diphenylphosphine) .Example 2: Preparation of the ligand (R) - CH 2 COOBIPHEP (Abstract A): (R) -6, 6 '-acetoxybiphenyl-2, 2' - diyl bis (diphenylphosphine).
Sous azote, dans un ballon tetracol de 250 ml, mettre en suspension le (R) -HOBIPHEP (5,65 g ; 1.01.10"2 mol) dans 100ml de DMF .Additionner à 20/24°C du K2C03 (7 g) . Après 10 mn d'agitation, introduire lentement au goutte à goutte, le chlorure d'acetyle (1,7 g ; 2,14.10~2 mol). On maintient à une température de 24/25 °C pendant 48 heures.Under nitrogen, in a four-necked 250 ml flask, suspending the (R) -HOBIPHEP (5.65 g;. 1 01.10 "2 mol) in 100 ml of DMF .Additionner to 20/24 ° C K 2 C0 3 (7 g) After 10 minutes of stirring, slowly introduce acetyl chloride (1.7 g; 2.14.10 ~ 2 mol) dropwise. Maintain at a temperature of 24/25 ° C for 48 hours.
On concentre le milieu réactionnel. Le résidu est repris avec une solution de 220 ml d'acétate d'éthyle et de 50 ml d'eau.The reaction medium is concentrated. The residue is taken up with a solution of 220 ml of ethyl acetate and 50 ml of water.
Après décantation, on lave la phase organique avec une solution de chlorure de sodium (3 fois 30 ml) . La phase organique est séchée, filtrée puis concentrée sous vide. On obtient 4,5 g de produit sous forme de cristaux marrons clairs.After decantation, the organic phase is washed with a sodium chloride solution (3 times 30 ml). The organic phase is dried, filtered and then concentrated in vacuo. 4.5 g of product are obtained in the form of clear brown crystals.
Le produit est purifié par chromatographie sur colonne. Eluant : CH2C12/ Hexane (1/2)The product is purified by column chromatography. Eluent: CH 2 C1 2 / Hexane (1/2)
On obtient 3,35 g de produit sous forme de cristaux blancs.3.35 g of product are obtained in the form of white crystals.
Rdt : 59 % en produit purifié. [α]D 23 : + 52,4 °Yield: 59% in purified product. [α] D 23 : + 52.4 °
Spectre RMN XH : 7,4-7,05 ppm (m,26H,H arom.); 1,7 ppm (S, 6H,CH3CO) . Spectre RMN 13C : 168,9 (CO) ; 122,8-148,9 (C arom.) ; 20,5 (C méthyle) .
Exemple 3 : Préparation du ligand (R)- (CH„),CHCOOBIPHEP (Abrégé B) : (R) - 6 , 6 ' -isobutanoyloxy biphenyl-2 , 2 ' -diyl bis (diphenylphosphine) .NMR spectrum X H: 7.4 to 7.05 ppm (m, 26H, arom H.); 1.7 ppm (S, 6H, CH 3 CO). 13 C NMR spectrum: 168.9 (CO); 122.8-148.9 (C arom.); 20.5 (C methyl). Example 3: Preparation of the ligand (R) - (CH „), CHCOOBIPHEP (Abstract B): (R) - 6,6 '-isobutanoyloxy biphenyl-2, 2' -diyl bis (diphenylphosphine).
Dans un ballon tetracol de 250 ml, sous agitation, on met en suspension le (R) -HOBIPHEP (4 g ; 7,21.10"3 mol) dans 72 ml du THF. On refroidit le milieu à -20°C et on additionne du NaH (0,61 g ; 0,025 mol) . Le milieu est laissé sous agitation, à -20°C, pendant 1 heure. On refroidit le milieu à -30°C, pour additionner goutte à goutte, le chlorure de 1 ' isobutyrique acide à 98 % (1,6 ml ; 0,025 mol) . On laisse le milieu remonter à la température ambiante soit 20 °C (au bout d'1 heure) . Le milieu est hydrolyse avec 50 ml d'eau. La réaction est exothermique. On extrait avec 40 ml d'acétate d'éthyle. La phase organique est lavée à l'eau (20 ml) puis avec une solution aqueuse de chlorure de sodium (2 fois 20 ml) . La phase organique est séchée, filtrée puis concentrée sous vide.In a 250 ml tetracol flask, with stirring, the (R) -HOBIPHEP (4 g; 7.21 × 10 −3 mol) is suspended in 72 ml of THF. The medium is cooled to -20 ° C. and added NaH (0.61 g; 0.025 mol) The medium is left stirring, at -20 ° C., for 1 hour. The medium is cooled to -30 ° C., to add dropwise the chloride of 1 ' 98% acid isobutyric acid (1.6 ml; 0.025 mol) The medium is allowed to return to ambient temperature, ie 20 ° C. (after 1 hour). The medium is hydrolyzed with 50 ml of water. is exothermic. Extraction is carried out with 40 ml of ethyl acetate. The organic phase is washed with water (20 ml) then with an aqueous solution of sodium chloride (twice 20 ml). The organic phase is dried, filtered and then concentrated in vacuo.
On obtient 5,6 g de produit sous forme d'une gomme marron.5.6 g of product are obtained in the form of a brown gum.
Le produit est purifié par chromatographie sur colonne. Eluant : CH2C12/ Hexane (1/2)The product is purified by column chromatography. Eluent: CH 2 C1 2 / Hexane (1/2)
On obtient 2,36 g de produit sous forme de cristaux blancs. Rdt: 31,4 % en produit purifié.2.36 g of product are obtained in the form of white crystals. Yield: 31.4% in purified product.
[α]D 23 : + 49,6 °[α] D 23 : + 49.6 °
Spectre RMN XH : 7,2-7,55 ppm (m,26H,H arom. ) ; 2,2-2,35 ppm (m, 2H, -CH-) , 0,8-1,05 ppm (m, 12H, (CH3) 2-) .NMR spectrum X H: 7.2 to 7.55 ppm (m, 26H, arom H.); 2.2-2.35 ppm (m, 2H, -CH-), 0.8-1.05 ppm (m, 12H, (CH 3 ) 2 -).
Spectre RMN 13C : 175 (CO) ; 123-149 (C arom.) ; 34(CH-) ; 19 (C méthyle) . 13 C NMR spectrum: 175 (CO); 123-149 (C arom.); 34 (CH-); 19 (C methyl).
Exemple 4 : Préparation du ligand(R)-Example 4: Preparation of the ligand (R) -
(CH3) CCOQBIPHEP (Abrégé ÇJ : (R) - 6 , 6 ' - tertiobutanoyloxybiphenyl-2 , 2 ' -diyl bis (diphenylphosphine) .
Selon le même procédé que 1 ' exemple 2.(CH 3 ) CCOQBIPHEP (Abbreviated ÇJ: (R) - 6,6 '- tertiobutanoyloxybiphenyl-2, 2' -diyl bis (diphenylphosphine). According to the same process as 1 example 2.
Rdt: 58 %.YId: 58%.
Spectre RMN 1H : 7,05-7,4 ppm (m,26H,H arom. ) ; 0, 8 ppm (m,18H, (CH3) ) . Spectre RMN 13C : 176 (CO) ; 122,8-149 (C arom.) ; 39,5(C) ; 28 (C méthyle) . 1 H NMR spectrum: 7.05-7.4 ppm (m, 26H, aromatic H); 0.8 ppm (m, 18H, (CH 3 )). 13 C NMR spectrum: 176 (CO); 122.8-149 (C arom.); 39.5 (C); 28 (C methyl).
Exemple 5 .-Préparation du ligand (R) -Example 5.-Preparation of the ligand (R) -
( CH, ) ,CHCHZC OOBIPHEP (Abrégé D) : (R) -6 , 6 ' - isovaleroyloxybiphenyl-2 , 2 ' -diyl bis (diphenylphosphine) .(CH,), CHCH Z C OOBIPHEP (Abstract D): (R) -6,6 '- isovaleroyloxybiphenyl-2, 2' -diyl bis (diphenylphosphine).
Selon le mode opératoire de 1 ' exemple 3.According to the procedure of Example 3.
Le milieu réactionnel est laissé 24 heures à 20°C, avant l'hydrolyse.The reaction medium is left for 24 hours at 20 ° C, before hydrolysis.
On obtient 5 , 1 g de produit sous forme d'huile. Après purification par chromatographie sur colonne. Eluant : CH2C12/ Hexane (1/2)5.1 g of product are obtained in the form of an oil. After purification by column chromatography. Eluent: CH 2 C1 2 / Hexane (1/2)
On obtient 1,7 g de produit sous forme de cristaux blancs.1.7 g of product are obtained in the form of white crystals.
Rdt: 37 % en produit purifié. Spectre RMN αH : 7,2-7,55 ppm (m,26H,H arom. ) ;Yid: 37% in purified product. Α H NMR spectrum: 7.2-7.55 ppm (m, 26H, aromatic H);
1,85-2,05 ppm (m, 6H, CH2CH-) , 0,95 ppm (d, 12H, (CH3) 2-) .1.85-2.05 ppm (m, 6H, CH 2 CH-), 0.95 ppm (d, 12H, (CH 3 ) 2 -).
Spectre RMN α3C : 171 (CO) ; 123-149,4 (C arom.) ; 43,1(CH-) ; 25,6 (CH2) ; 22,7 (C méthyle). Α3 C NMR spectrum : 171 (CO); 123-149.4 (C arom.); 43.1 (CH-); 25.6 (CH 2 ); 22.7 (C methyl).
Exemple 6 : Préparation du ligand (R)-Example 6: Preparation of the ligand (R) -
C.H^COOBIPHEP (Abrégé E) : (R) -6 , 6 ' -benzoyloxybiphenyl-2 , 2 ' - diyl bis (diphenylphosphine) .C.H ^ COOBIPHEP (Abstract E): (R) -6, 6 '-benzoyloxybiphenyl-2, 2' - diyl bis (diphenylphosphine).
Dans un tétracol de 500 ml, sous azote, mettre NaH (2,6 g ; 0,108 mol) dans du THF (64 ml). Additionner à 20 °C, le (R) -HOBIPHEP (0,0257 mol) en solution dans du DMF (64 ml) pendant 45 mn. Laisser sous agitation à 20 °C pendant 1 heure. Refroidir le milieu à -40°C. Introduire le chlorure de benzoyle (8,18 ml source
Fluka) au goutte à goutte pendant 20 mn. Maintenir le milieu à -40/45 °C pendant 45 mn.In a 500 ml tetracol, under nitrogen, put NaH (2.6 g; 0.108 mol) in THF (64 ml). Add the (R) -HOBIPHEP (0.0257 mol) dissolved in DMF (64 ml) for 45 min at 20 ° C. Leave to stir at 20 ° C for 1 hour. Cool the medium to -40 ° C. Introduce benzoyl chloride (8.18 ml source Fluka) drop by drop for 20 min. Maintain the medium at -40 / 45 ° C for 45 min.
Additionner une solution à 10 % d'acide chlorhydrique (75 ml) . Laisser remonter la température à 0°C durantAdd a 10% hydrochloric acid solution (75 ml). Let the temperature rise to 0 ° C for
1 ' introduction .1 introduction.
L'hydrolyse terminée, ramener à la température ambiante . Extraire le milieu avec de l'acétate d'éthyle (50 ml et 40 ml) . Laver la phase organique à l'eau (2 fois 20 ml) . La phase organique est séchée, filtée puis concentrée sous vide.After the hydrolysis, bring back to room temperature. Extract the medium with ethyl acetate (50 ml and 40 ml). Wash the organic phase with water (twice 20 ml). The organic phase is dried, filtered and then concentrated in vacuo.
On obtient le produit attendu sous forme d'huile marron.The expected product is obtained in the form of a brown oil.
Après purification par chro atographie sur colonne. Eluant : Hexane puis Toluène.After purification by column chromatography. Eluent: Hexane then Toluene.
On obtient le produit sous forme de cristaux blancs .The product is obtained in the form of white crystals.
Rdt: 55,2 % en produit purifié.Yield: 55.2% in purified product.
Spectre RMN XH : 7-7,55 ppm (m, H arom.) Spectre RMN 13C : 164 (CO) ; 123-149 (C arom.).H NMR spectrum X: from 7 to 7.55 ppm (m, H arom.) 13 C-NMR spectrum: 164 (CO); 123-149 (C arom.).
Exemple 7 : Préparation du ligand (R)-Example 7: Preparation of the ligand (R) -
CJi C OOBIPHEP (Abrégé 7) : (R) - 6 , 6 ' -CJi C OOBIPHEP (Abstract 7): (R) - 6, 6 '-
Cyclohexanoyloxybiphenyl-2 , 2 ' -diyl bis (diphenylphosphine) . Selon le même procédé que celui de l'exemple 6, sans purification par chromatographie sur colonne.Cyclohexanoyloxybiphenyl-2, 2 '-diyl bis (diphenylphosphine). According to the same process as that of Example 6, without purification by column chromatography.
On obtient le produit sous forme de cristaux blancs .The product is obtained in the form of white crystals.
Rdt: 52,5 % en produit. Spectre RMN XH : 7,15-7,5 ppm (m,26H,H arom.);Yid: 52.5% in product. NMR spectrum X H: 7.15 to 7.5 ppm (m, 26H, arom H.);
1,9 ppm (m,2H,-CH-), 1-1,6 ppm (m, 20H, - (CH2) -) .1.9 ppm (m, 2H, -CH-), 1-1.6 ppm (m, 20H, - (CH 2 ) -).
Spectre RMN 13C : 172 (CO) ; 123-149,5 (C arom.) ; 43 (CH-) ; 26 et 28 ppm (CH2) .
Exemple 8 : Préparation du ligand(R)- (C4H3Q) COOBIPHEP (Abrégé G) : (R)-6,6'-2- Furanoyloxybiphenyl-2 , 2 ' -diyl bis (diphenylphosphine) . 13 C NMR spectrum: 172 (CO); 123-149.5 (C arom.); 43 (CH-); 26 and 28 ppm (CH 2 ). Example 8: Preparation of the ligand (R) - (C 4 H 3 Q) COOBIPHEP (Abbreviated G): (R) -6,6'-2- Furanoyloxybiphenyl-2, 2 '-diyl bis (diphenylphosphine).
Selon le même procédé que celui de l'exemple 6, avec purification par chromatographie sur colonne. Eluant CH2CL2.According to the same process as that of Example 6, with purification by column chromatography. Eluent CH 2 CL 2 .
On obtient le produit sous forme de cristaux blancs ou jaunes pâles.The product is obtained in the form of white or pale yellow crystals.
Rdt: 84,2 % en produit purifié.Yield: 84.2% in purified product.
Spectre RMN ^Η : 7,6-6,35 ppm (m, H arom.+ H furyl) .Η NMR spectrum: 7.6-6.35 ppm (m, H arom. + H furyl).
Spectre RMN α3C : 156 (CO) ; 110-149 (C arom.). Α3 C NMR spectrum : 156 (CO); 110-149 (C arom.).
Exemple 9 : Préparation du ligand (R) -Example 9: Preparation of the ligand (R) -
CH_0CH,C OOBIPHEP (Abrégé H) : (R) - 6 , 6 ' -CH_0CH, C OOBIPHEP (Abbreviated H): (R) - 6, 6 '-
Methoxyacetyloxybiphenyl-2 , 2 ' -diyl bis (diphenylphosphine) .Methoxyacetyloxybiphenyl-2, 2 '-diyl bis (diphenylphosphine).
Selon le même procédé que celui de l'exemple 6 sans purification par chromatographie sur colonne.According to the same process as that of Example 6 without purification by column chromatography.
On obtient le produit sous forme de cristaux blancs ou jaunes pâles.The product is obtained in the form of white or pale yellow crystals.
Rdt: 34,8 % en produit.YId: 34.8% in product.
Spectre RMN XH : 7,4-7,08 ppm (m,26H,H arom. ) ; 3,6 ppm (s,4H,-0CH20-) , 3,25 ppm (s, 6H, CH30-) .NMR spectrum X H: 7.4 to 7.08 ppm (m, 26H, arom H.); 3.6 ppm (s, 4H, -0CH 2 0-), 3.25 ppm (s, 6H, CH 3 0-).
Spectre RMN 13C : 169 (CO) ; 123-149 (C arom.) ; 69(CH20-) ; 60 (C éthoxy) . 13 C NMR spectrum: 169 (CO); 123-149 (C arom.); 69 (CH 2 0-); 60 (C ethoxy).
II - Préparation de catalyseursII - Preparation of catalysts
Exemple 10 : Préparation du catalyseur : Le complexe [RuBr, (R) -CH3COOBIPHEP) ] , . acétone .Example 10: Preparation of the catalyst: The complex [RuBr, (R) -CH 3 COOBIPHEP)],. acetone.
Dans une bombe à hydrogénation, introduire le ligand (R) - CH3COOBIPHEP (20,8 mg ; 0,032 mol) et du 1,5- bis methylallylcyclooctadiène ruthénium (8,4 mg ; 0.026 mol) dans 1,5 ml d'acétone. On additionne ensuite, via une seringue, de l'acide bromhydrique en solution dans du methanol (0,128 ml d'une solution 0,5 M). On laisse 15 mn à 20 °C, sous agitation.In a hydrogenation bomb, introduce the ligand (R) - CH 3 COOBIPHEP (20.8 mg; 0.032 mol) and 1,5- bis methylallylcyclooctadiene ruthenium (8.4 mg; 0.026 mol) in 1.5 ml of acetone. Hydrobromic acid dissolved in methanol (0.128 ml of a 0.5 M solution) is then added via a syringe. It is left for 15 min at 20 ° C., with stirring.
On obtient une solution catalytique du complexe [RuBr2 (R- CH3COOBIPHEP) ] 2. acétone .A catalytic solution of the complex [RuBr 2 (R-CH 3 COOBIPHEP)] 2 is obtained. acetone.
Exemple 11 : Préparation du catalyseur : Le complexe Ru (R) -CTCOOBIPHEP) (OAc),.Example 11: Preparation of the catalyst: The Ru (R) -CTCOOBIPHEP) (OAc) complex.
Dans un tétracol de 100 ml, sous azote, introduire le ligand (R) - CH3COOBIPHEP (8 g) dans du toluène (50 ml) .In a 100 ml tetracol, under nitrogen, introduce the ligand (R) - CH 3 COOBIPHEP (8 g) in toluene (50 ml).
Additionner l'acétate de sodium (4,48 g), le ruthénium cyclooctadiène dichlorure (CODRuCl2) (3,85 g).Add sodium acetate (4.48 g), ruthenium cyclooctadiene dichloride (CODRuCl2) (3.85 g).
Additionner rapidement l'acide acétique (15,5 g). On chauffe au reflux (93°C) pendant 22 heures.Quickly add the acetic acid (15.5 g). The mixture is heated at reflux (93 ° C) for 22 hours.
Refroidir à 65 °C . Dis tiller sous vide, l'azeotrope acide acétique/ toluène . Recharger en toluène (40 ml) pour entrainer l'acide acétique jusqu'à un volume résiduel de 20 ml.
Refroidir à 50°C et introduire de l'acétone (112 ml) .Laisser refroidir à 20°C et agiter pendant 1 heure .Cool to 65 ° C. Dispense under vacuum, the acetic acid / toluene azeotrope. Reload with toluene (40 ml) to entrain the acetic acid to a residual volume of 20 ml. Cool to 50 ° C and introduce acetone (112 ml). Let cool to 20 ° C and stir for 1 hour.
Filtrer et concentrer le filtrat. Le résidu est repris avec du toluène puis concentrer (2 fois 20 ml) .Filter and concentrate the filtrate. The residue is taken up with toluene and then concentrated (twice 20 ml).
A 70 °C, additionner goutte à goutte au concentrât, sous agitation, de l'heptane (52 ml) (durée de l'addition 52 min.).At 70 ° C, add dropwise to the concentrate, with stirring, heptane (52 ml) (duration of the addition 52 min.).
Laisser refroidir à 20 °C . Filtrer et rincer avec de l'heptane (2 fois 20 ml). Sécher sous cloche.Let cool to 20 ° C. Filter and rinse with heptane (2 times 20 ml). Dry in a bell.
On obtient des cristaux vert-foncé.Dark green crystals are obtained.
Rdt: 30,2 % .Yid: 30.2%.
Analyse élémentaire : 58 , 6 % C ; 4 , 6 % H .Elemental analysis: 58.6% C; 4.6% H.
Exemple 12 : Préparation du catalyseur : Le complexe Ru (R) - (CHJ ,CHCQOBIPHEP) (OAc ) , .Example 12: Preparation of the catalyst: The Ru (R) - (CHJ, CHCQOBIPHEP) (OAc) complex.
Selon le même procédé que celui de l ' exemple 11 . On obtient des cristaux vert-foncé . Rdt : 83 % .According to the same process as that of Example 11. Dark green crystals are obtained. Yid: 83%.
Les exemples 13 à 19 suivent le même procédé que celui de l ' exemple 10 .Examples 13 to 19 follow the same procedure as that of Example 10.
III - Application en hydrogénation asymétrique .III - Application in asymmetric hydrogenation.
Exemple 2 0 : Hydrogénation asymétrique de 1 ' ethylbenzoylacétate . Ligand du catalyseur : A.Example 20: Asymmetric hydrogenation of ethylbenzoylacetate. Catalyst ligand: A.
A la solution catalytique de l'exemple 10, on additionne du benzoylacetate d'éthyle (0,5 g ; 0,0026 mol) et 5 ml d'ethanol. On met sous une pression de 20 bars d'hydrogène. Le milieu est chauffé à 50°C et laissé 22 heures sous agitation. To the catalytic solution of Example 10, ethyl benzoylacetate (0.5 g; 0.0026 mol) and 5 ml of ethanol are added. One puts under a pressure of 20 bars of hydrogen. The medium is heated to 50 ° C. and left stirring for 22 hours.
On concentre le milieu.The medium is concentrated.
On obtient 0,54 g de produit sous forme d'un liquide brun.0.54 g of product is obtained in the form of a brown liquid.
Rdt : Pureté chimique : 82 % e.e. : 97,8 %Yield: Chemical purity: 82% e.e. : 97.8%
Exemples 21 à 23 : Même mode opératoire que celui de l'exemple 20 avec les ligands B, C ou D.Examples 21 to 23: Same procedure as that of Example 20 with ligands B, C or D.
Exemple 24 : Hydrogénation asymétrique du composé hydroxyacetone . Ligand A.Example 24: Asymmetric hydrogenation of the hydroxyacetone compound. Ligand A.
5 bars, 60 °C
5 bars, 60 ° C
Cat.: [Ru-(R)-PhosphineA-Br2]2 S/C = 1/3000Cat .: [Ru- (R) -PhosphineA-Br 2 ] 2 S / C = 1/3000
On effectue le même procédé que celui de l'exemple 20 en tenant compte de la pression d'hydrogène, de la température et du rapport substrat/catalyseur (S/C) indiqué dans la réaction.The same process is carried out as that of Example 20, taking into account the hydrogen pressure, the temperature and the substrate / catalyst ratio (S / C) indicated in the reaction.
On obtient le produit attendu sous forme d'un liquide brun.The expected product is obtained in the form of a brown liquid.
Rdt : Pureté chimique : 72,7 % e.e. : 96,1 %
Exemples 25 à 33 : Même mode opératoire que celui de l'exemple 24 avec les ligands B, C, D, E, F, G ou H . Catalyseur [RuL*Br2] .Yield: Chemical purity: 72.7% ee: 96.1% Examples 25 to 33: Same procedure as that of Example 24 with ligands B, C, D, E, F, G or H. Catalyst [RuL * Br 2 ].
Exemple 34 : Hydrogénation asymétrique du composé hydroxyacetone .Example 34: Asymmetric hydrogenation of the hydroxyacetone compound.
4 bars, 35 °C
4 bars, 35 ° C
Ca : [Ru-(R)-PhosphineA-Br2]2 S/C = 1/300Ca: [Ru- (R) -PhosphineA-Br 2 ] 2 S / C = 1/300
On effectue le même procédé que celui de l'exemple 20 en tenant compte de la pression d'hydrogène, de la température et du rapport substrat/catalyseur (S/C) indiqué dans la réaction.The same process is carried out as that of Example 20, taking into account the hydrogen pressure, the temperature and the substrate / catalyst ratio (S / C) indicated in the reaction.
On obtient le produit attendu sous forme d'un liquide brun.The expected product is obtained in the form of a brown liquid.
Rdt : 80-95 % e.e. : 97 %Yid: 80-95% e.e. : 97%
Exemples 35 à 39 : Même mode opératoire que celui de l'exemple 34 avec les ligands B, C , D, E, F, G ou H . Catalyseur [RuL*Br2] .
Examples 35 to 39: Same procedure as that of Example 34 with ligands B, C, D, E, F, G or H. Catalyst [RuL * Br 2 ].
Exemple 40 : Hydrogénation asymétrique du composé 4-chloroacétoacétate.Example 40: Asymmetric hydrogenation of the 4-chloroacetoacetate compound.
8 bars, 95 °C
Et
cal: Ru-(R)-PhosphineA-(OAc) 2 S/C = 1/20008 bar, 95 ° C And cal: Ru- (R) -PhosphineA- (OAc) 2 S / C = 1/2000
On effectue le même procédé que celui de l'exemple 20 en tenant compte de la pression d'hydrogène, de la température et du rapport substrat/catalyseur (S/C) indiqué dans la réaction.The same process is carried out as that of Example 20, taking into account the hydrogen pressure, the temperature and the substrate / catalyst ratio (S / C) indicated in the reaction.
On obtient le produit attendu sous forme d'une huile.The expected product is obtained in the form of an oil.
Rdt : Quantitatif Pureté chimique : 52 % e.e. : 94 %.Yield: Quantitative Chemical purity: 52% e.e. : 94%.
Exemples 41 : Même mode opératoire que celui de l'exemple 40 avec le ligand B. Catalyseur [RuL*Br,] .Examples 41: Same procedure as that of Example 40 with the ligand B. Catalyst [RuL * Br,].
* : condition de température : 75°C*: temperature condition: 75 ° C
Exemple 42 : Hydrogénation asymétrique du composé Acetamide, N- [1- (2-naphthaïenyl) ethenyl] . Ligand A.
Example 42: Asymmetric hydrogenation of the compound Acetamide, N- [1- (2-naphthaïenyl) ethenyl]. Ligand A.
On effectue le même procédé que celui de l'exemple 20 en tenant compte de la pression d'hydrogène, de la température et du rapport substrat/catalyseur (S/C) indiqué dans la réaction.The same process is carried out as that of Example 20, taking into account the hydrogen pressure, the temperature and the substrate / catalyst ratio (S / C) indicated in the reaction.
On obtient le produit attendu sous forme d'une huile orange .The expected product is obtained in the form of an orange oil.
Rdt : 80-90 e.e. : 85,8 %.Yid: 80-90 e.e. : 85.8%.
Exemples 43 à 47 : Même mode opératoire que celui de l'exemple 42 avec les ligands B, C, E, F et G. Catalyseur [RuL*Br?] .Examples 43 to 47: Same procedure as that of Example 42 with ligands B, C, E, F and G. Catalyst [RuL * Br ? ].
Exemple 48 : Hydrogénation asymétrique du composé Itaconate de dimethyl . Ligand A.Example 48: Asymmetric hydrogenation of the dimethyl Itaconate compound. Ligand A.
V CO2CH3 2 bars, 20 °C Me. ., CO2 2CH" "3V CO 2 CH 3 2 bars, 20 ° C Me . , CO 2 2CH "" 3
>C02CH3 cat: Ru-(R)-PhosphineA-(Br) 2 OO2CH3 S/C = 1/100
On effectue le même procédé que celui de l'exemple 20 en tenant compte de la pression d'hydrogène, de la température et du rapport substrat/catalyseur (S/C) indiqué dans la réaction. > C0 2 CH 3 cat: Ru- (R) -PhosphineA- (Br) 2 OO 2 CH 3 S / C = 1/100 The same process is carried out as that of Example 20, taking into account the hydrogen pressure, the temperature and the substrate / catalyst ratio (S / C) indicated in the reaction.
On obtient le produit attendu sous forme d'un liquide brun.The expected product is obtained in the form of a brown liquid.
Rdt : 80-90 % e.e. : 97,4 % .Yid: 80-90% e.e. : 97.4%.
Exemples 49 à 53 : Même mode opératoire que celui de l'exemple 48 avec les ligands C, E, F, G et H. Catalyseur [RuL*Br,] .Examples 49 to 53: Same procedure as that of Example 48 with ligands C, E, F, G and H. Catalyst [RuL * Br,].
Claims
REVENDICATIONS
1) Utilisation d'une diphosphine chirale (R) ou (S) de formule (I) :1) Use of a chiral diphosphine (R) or (S) of formula (I):
dans laquelle :in which :
R et Ri, identiques ou différents, représentent un groupement alkyle en C^o saturé ou non, un groupement cycloalkyle en C3_9 saturé ou non, un groupement aryle en C5_10, lesdits groupements étant éventuellement substitués par un halogène, un hydroxy, un alkoxy en C _5 r un amino tel que NH2 , NHR4, N(R4)2, un sulfino, un sulfonyle, avec R4 représentant un alkyle, un alkoxy ou un alkylcarbonyle, lesdits groupements alkyle, cycloalkyle, aryle comprennant éventuellement un ou plusieurs hétéroatome tel que 0, N, S, Si, ou encore R et Ri, ensemble, représentent un groupement alkyle substitué en C2_s saturé ou non, un groupement cycloalkyle en C3_9 saturé ou non, un groupement aryle en C5_10, lesdits groupements cycloalkyle et aryle étant éventuellement substitués par un alkyle en C-^, un halogène, un hydroxy, un alkoxy en Cl_5 , un amino tel que NH2, NHR4 , N(R4)2, un sulfino, un sulfonyle, avec R4 représentant un alkyle, un alkoxy ou un alkylcarbonyle, lesdits groupements alkyle, cycloalkyle, aryle comprennent éventuellement un ou plusieurs hétéroatome tel que 0, N, S, Si ;
R2 et R3 , identiques ou différents, représentent un groupement cycloalkyle en C3_8 saturé ou non, un aryle en C5_10, lesdits groupements étant éventuellement substitués par un halogène, un hydroxy, un alkoxy en Cx_5 , un amino tel que NH2 , NHR4 , N(R4)2, un sulfino, un sulfonyle, avec R4 représentant un alkyle, un alkoxy ou un alkylcarbonyle, lesdits groupements cycloalkyle, aryle comprennant éventuellement un ou plusieurs hétéroatome tel que 0, N, S, Si, ou encore, R2 et R3 forment ensemble un groupement carbocycle en C4_8 saturé ou non , un groupement aryle en C6_10, lesdits groupements étant éventuellement substitués par un halogène, un hydroxy, un alkoxy en C1_5, un amino tel que NH2 , NHR4 , N(R4)2, un sulfino, un sulfonyle, avec R4 représentant un alkyle, un alkoxy ou un alkylcarbonyle, lesdits groupements carbocycle, aryle comprennant éventuellement un ou plusieurs hétéroatome tel que 0, N, S, Si ; comme ligand optiquement actif pour la préparation d'un complexe diphosphino-métallique.R and R, identical or different, represent an alkyl group C ^ o saturated or unsaturated cycloalkyl, C 3 _ 9 saturated or unsaturated, an aryl group, C 5 _ 10, said groups being optionally substituted by halogen, hydroxy, C _ 5 alkoxy r amino such as NH 2 , NHR 4 , N (R 4 ) 2 , sulfino, sulfonyl, with R 4 representing an alkyl, an alkoxy or an alkylcarbonyl, said alkyl groups, cycloalkyl, aryl optionally comprising one or more heteroatoms such as 0, N, S, Si, or also R and Ri, together, represent a substituted C 2 _ s alkyl group, saturated or unsaturated, a C 3 _ 9 cycloalkyl group or not, a C 5 _ 10 aryl group, said cycloalkyl and aryl groups being optionally substituted by a C 1 -C 4 alkyl, a halogen, a hydroxy, a C 1 -C 5 alkoxy, an amino such as NH 2 , NHR 4 , N (R 4 ) 2 , a sulfino, a sulfonyl, with R 4 representing an alkyl, an alkoxy or an alkylcarbonyl, said alkyl, cycloalkyl or aryl groups optionally comprise one or more heteroatoms such as 0, N, S, Si; R2 and R3, identical or different, represent a C 3 _ 8 cycloalkyl group, saturated or unsaturated, a C 5 _ 10 aryl, said groups being optionally substituted by a halogen, a hydroxy, a C x _ 5 alkoxy, a amino such as NH 2 , NHR 4 , N (R 4 ) 2 , a sulfino, a sulfonyl, with R 4 representing an alkyl, an alkoxy or an alkylcarbonyl, said cycloalkyl or aryl groups possibly comprising one or more heteroatoms such as 0, N, S, Si, or also R2 and R3 together form a C 4 _ 8 carbocycle group, saturated or not, a C 6 _ 10 aryl group, said groups being optionally substituted by a halogen, a hydroxy, an alkoxy in C 1 _ 5 , an amino such as NH 2 , NHR 4 , N (R 4 ) 2 , a sulfino, a sulfonyl, with R 4 representing an alkyl, an alkoxy or an alkylcarbonyl, said carbocycle or aryl groups optionally comprising one or several heteroatoms such as 0, N, S, Si; as an optically active ligand for the preparation of a diphosphino-metallic complex.
2) Utilisation selon la revendication 1, caractérisée en ce que le complexe diphosphino-métallique répond à la formule (II) suivante : MxHyXz(L)2 (Sv)p (II) dans laquelle,2) Use according to claim 1, characterized in that the diphosphino-metallic complex corresponds to the following formula (II): M x H y X z (L) 2 (Sv) p (II) in which,
M représente un métal tel que le ruthénium, le rhodium ou 1 ' irridium ;M represents a metal such as ruthenium, rhodium or irridium;
X représente un halogène tel que le chlore, le brome, le fluor ou l'iode ;X represents a halogen such as chlorine, bromine, fluorine or iodine;
Sv représente une aminé tertiaire, une cétone, un éther ;Sv represents a tertiary amine, a ketone, an ether;
L représente une diphosphine chirale (R) ou (S), de formule (I) définie dans la revendication 1;
y est un nombre entier, égale à 0 ou 1 x est un nombre entier, égale à 1 ou 2 z est un nombre entier, égale à 1 ou 4 p est un nombre entier, égale à 0 ou 1 .L represents a chiral diphosphine (R) or (S), of formula (I) defined in claim 1; y is an integer, equal to 0 or 1 x is an integer, equal to 1 or 2 z is an integer, equal to 1 or 4 p is an integer, equal to 0 or 1.
3) Utilisation selon l'une des revendications 1 ou 2, caractérisée en ce que le complexe diphosphino- métallique répond à la formule (IIA) suivante :3) Use according to one of claims 1 or 2, characterized in that the diphosphino-metallic complex corresponds to the following formula (IIA):
M2X4L2 (Sv) (IIA) dans laquelle M, X, L et Sv ont la même signification que dans la formule (II) définie à la revendication 2.M 2 X 4 L 2 (Sv) (IIA) in which M, X, L and Sv have the same meaning as in formula (II) defined in claim 2.
4) Utilisation selon l'une des revendications 1 à 3, caractérisée en ce que le complexe diphosphino- métallique est choisi parmi :4) Use according to one of claims 1 to 3, characterized in that the diphosphino-metallic complex is chosen from:
- Ru4Cl2[ (R) ou (S) CH3C00-Binap]2. N(Et)3 , aussi désigné Di [2 , 2 ' -bis (diphenylphosphino) (R) ou (S) - 6 , 6 ' -di acé t oxybiphenyl ] -tetrachloro diruthénium triethylamine,- Ru 4 Cl 2 [(R) or (S) CH 3 C00-Binap] 2 . N (Et) 3 , also designated Di [2, 2 '-bis (diphenylphosphino) (R) or (S) - 6,6' -di acé t oxybiphenyl] -tetrachloro diruthenium triethylamine,
- Ru4Cl2 ( (Me) 2CHC00-Binap) 2. N(Et)3 , aussi désigné Di [2 , 2 ' -bis (diphenylphosphino) (R) ou (S)-6,6'-di- is obutanoyl oxybiphenyl ] -tetrachloro diruthénium triethylamine , - Ru4Cl2 ( (CH3) 3CCOO-Binap) 2. N(Et)3 , aussi désigné Di [2 , 2 ' -bis (diphenylphosphino) (R) ou (S) -6, 6'- di trimethylacetoxybiphenyl ] -tetrachloro diruthénium triethylamine ,- Ru 4 Cl 2 ((Me) 2 CHC00-Binap) 2 . N (Et) 3 , also designated Di [2, 2 '-bis (diphenylphosphino) (R) or (S) -6,6'-di- is obutanoyl oxybiphenyl] -tetrachloro diruthenium triethylamine, - Ru 4 Cl 2 (( CH 3 ) 3 CCOO-Binap) 2 . N (Et) 3 , also designated Di [2, 2 '-bis (diphenylphosphino) (R) or (S) -6, 6'- di trimethylacetoxybiphenyl] -tetrachloro diruthenium triethylamine,
- Ru4Cl2( (Me)2CHCH2COO-Binap)2. N(Et)3, - Ru4Cl2(CH3COO-Binap)2. CO(Me)2,- Ru 4 Cl 2 ((Me) 2 CHCH 2 COO-Binap) 2 . N (Et) 3 , - Ru 4 Cl 2 (CH 3 COO-Binap) 2 . CO (Me) 2 ,
- Ru4Br2 (CH3COO-Binap)2. N(Et)3,- Ru 4 Br 2 (CH 3 COO-Binap) 2 . N (And) 3 ,
- Ru4Br2( (Me)2CHCOO-Binap)2. N(Et)3,- Ru 4 Br 2 ((Me) 2 CHCOO-Binap) 2 . N (And) 3 ,
- Ru4Br2( (CH3)3CCOO-Binap)2. N(Et)3,- Ru 4 Br 2 ((CH 3 ) 3 CCOO-Binap) 2 . N (And) 3 ,
- Ru4Br2( (Me)2CHCH2COO-Binap)2. N(Et)3,
Ru4Br2 (CH3COO-Binap)2. CO(Me)2, Ru4Br2 ( (Me ) 2CHCOO-Binap ) 2. CO (Me ) 2 , Ru4Br2 ( ( CH3 ) 3CCOO-Binap ) 2. CO (Me ) 2 , Ru4Br2( (Me)2CHCH2COO-Binap)2. CO(Me)2, Ru4Br2 (C6H5COO-Binap)2. CO(Me)2, Ru4Br2 (C6H1:LCOO-Binap)2. CO(Me)2, Ru4Br2 (C4H3OCOO-Binap)2. CO(Me)2, Ru4Br2 (CH3OCH2COO-Binap)2. CO(Me)2.- Ru 4 Br 2 ((Me) 2 CHCH 2 COO-Binap) 2 . N (And) 3 , Ru 4 Br 2 (CH 3 COO-Binap) 2 . CO (Me) 2 , Ru 4 Br 2 ((Me) 2 CHCOO-Binap) 2 . CO (Me) 2 , Ru 4 Br 2 ((CH 3 ) 3 CCOO-Binap) 2 . CO (Me) 2 , Ru 4 Br 2 ((Me) 2 CHCH 2 COO-Binap) 2 . CO (Me) 2 , Ru 4 Br 2 (C 6 H 5 COO-Binap) 2 . CO (Me) 2 , Ru 4 Br 2 (C 6 H 1: L COO-Binap) 2 . CO (Me) 2 , Ru 4 Br 2 (C 4 H 3 OCOO-Binap) 2 . CO (Me) 2 , Ru 4 Br 2 (CH 3 OCH 2 COO-Binap) 2 . CO (Me) 2 .
5) Utilisation selon l'une des revendications 1 ou 2, caractérisée en ce que le complexe diphosphino- métallique répond à la formule (IIB) suivante :5) Use according to one of claims 1 or 2, characterized in that the diphosphino-metallic complex corresponds to the following formula (IIB):
MHXL2 (IIB) dans laquelle M, X et L ont la même signification que dans la formule (II) définie à la revendication 2 et H représente un atome d'hydrogène.MHXL 2 (IIB) in which M, X and L have the same meaning as in formula (II) defined in claim 2 and H represents a hydrogen atom.
6) Utilisation selon la revendication 1, caractérisée en ce que le complexe diphosphino-métallique répond à la formule (III) suivante : X.,(Ar)nI.Yn (III) dans laquelle,6) Use according to claim 1, characterized in that the diphosphino-metallic complex corresponds to the following formula (III): X., (Ar) n IY n (III) in which,
M, X, L ont la même signification que dans la formule (II) définie à la revendication 2;M, X, L have the same meaning as in formula (II) defined in claim 2;
Ar représente une oléfine telle que l'éthylène, le 1, 3-butadiène, le cyclohexadiene, le norbonadiene, le cycloocta-1 , 5-diène , un pi-allyle, un nitrile tel que 1 ' acetonitrile, un arène de formule (IV) :Ar represents an olefin such as ethylene, 1,3-butadiene, cyclohexadiene, norbonadiene, cycloocta-1,5-diene, a pi-allyl, a nitrile such as acetonitrile, an arene of formula ( IV):
où R5 , R6 , R7 , R8 , R9 et RIO, identiques ou différents, sont choisis parmi un atome d'hydrogène, un groupement alkyle en C1_5 , un groupement isoalkyle, un groupement tertioalkyle, un groupement alkoxy, lesdits groupements comprenant un ou plusieurs heteroatomes comme O, N et Si ; where R5, R6, R7, R8, R9 and RIO, identical or different, are chosen from a hydrogen atom, a C 1 _ 5 alkyl group, an isoalkyl group, a tertioalkyl group, an alkoxy group, said groups comprising one or more heteroatoms such as O, N and Si;
Y représente un anion, tel que C104 ~, BF4 ~, PF6 " ; j est un nombre entier égale à 0 ou 1 ; m est un nombre entier égale à 1,2 ou 4 ; n est un nombre entier égale à 1 ou 2.Y represents an anion, such as C10 4 ~ , BF 4 ~ , PF 6 " ; j is an integer equal to 0 or 1; m is an integer equal to 1.2 or 4; n is an integer equal to 1 or 2.
7) Utilisation selon la revendication 1, caractérisée en ce que le complexe diphosphino-métallique répond à la formule (V) suivante : [MX(P(R11)2(R12))L]2 X (V) dans laquelle7) Use according to claim 1, characterized in that the diphosphino-metallic complex corresponds to the following formula (V): [MX (P (R 11 ) 2 (R 12 )) L] 2 X (V) in which
M, X et L ont les mêmes définitions que dans la formule (II) définie à la revendication 2, et RX1 et R12, identiques ou différents, représentent un phényle ou un phényle substitué par un alkyle, un alkoxy ou un dialkylamino .M, X and L have the same definitions as in formula (II) defined in claim 2, and R X1 and R 12 , identical or different, represent a phenyl or a phenyl substituted by an alkyl, an alkoxy or a dialkylamino.
8) Utilisation selon la revendication 1, caractérisée en ce que le complexe diphosphino-métallique répond à la formule (VI) suivante :8) Use according to claim 1, characterized in that the diphosphino-metallic complex corresponds to the following formula (VI):
M(L)Z2 (VI) dans laquelle,M (L) Z 2 (VI) in which,
M et L ont la même signification que dans la formule (II) définie à la revendication 2 et Z représente un groupement acétate de formule R13COO", diacetate de formule "OOCR13COO", un aminoacetate de formule R13CH (NH2) COO" , où R13 représente un alkyle en C1-4, un halogénoalkyle en C1_4, un phényle substitué ou non.
9) Utilisation selon la revendication 1, caractérisée en ce que le complexe diphosphino-métallique répond à la formule (VII) suivante :M and L have the same meaning as in formula (II) defined in claim 2 and Z represents an acetate group of formula R 13 COO " , diacetate of formula " OOCR 13 COO " , an aminoacetate of formula R 13 CH (NH 2) COO ", where R 13 is C 1-4 alkyl, halo C 1 _ 4, a substituted or unsubstituted phenyl. 9) Use according to claim 1, characterized in that the diphosphino-metallic complex corresponds to the following formula (VII):
[M(L)WXk]n Z'p (VII) dans laquelle :[M (L) WX k ] n Z ' p (VII) in which:
M, L et X ont la même signification que dans la formule (II) définie à la revendication 2;M, L and X have the same meaning as in formula (II) defined in claim 2;
W représente du zinc, de l'aluminium, du titane ou de 1 ' étain ; Z' représente :W represents zinc, aluminum, titanium or tin; Z 'represents:
- soit un groupement acétate de formule R14COO~ où R14 représente un alkyle en C1_4, un halogénoalkyle C1_â, un phényle substitué ou non, et dans ce cas n=l et p=2 , et lorsque W est Zn alors k=2 , lorsque W est Al alors k=3 , et lorsque W est Ti ou Sn alors k=4, soit une aminé tertiaire, comme la triethylamine, et dans ce cas n=2 et p=l, et lorsque W est Zn alors k=4, lorsque W est Al alors k=5 et lorque W est Ti ou Sn alors k =6.- Or an acetate group of formula R 14 COO ~ where R 14 represents a C 1 _ 4 alkyl, a haloalkyl C 1 _ â , a substituted or unsubstituted phenyl, and in this case n = 1 and p = 2, and when W is Zn then k = 2, when W is Al then k = 3, and when W is Ti or Sn then k = 4, ie a tertiary amine, such as triethylamine, and in this case n = 2 and p = l, and when W is Zn then k = 4, when W is Al then k = 5 and when W is Ti or Sn then k = 6.
10) Utilisation selon la revendication 1, caractérisée en ce que le complexe diphosphino-métallique répond à la formule (VIII) suivante :10) Use according to claim 1, characterized in that the diphosphino-metallic complex corresponds to the following formula (VIII):
MH(L)2Y (VIII) dans laquelle H représente un atome d'hydrogène, M et L ont la même signification que dans la formule (II) définie à la revendication 2;MH (L) 2 Y (VIII) in which H represents a hydrogen atom, M and L have the same meaning as in formula (II) defined in claim 2;
Y représente un anion, tel que C104 ", BF4 ", PF6 ~ .Y represents an anion, such as C10 4 " , BF 4 " , PF 6 ~ .
11) Utilisation selon la revendication 1, caractérisée en ce que le complexe diphosphino-métallique répond à la formule (IX) suivante : M(L)Y2 (IX)
dans laquelle M et L ont la même signification que dans la formule (II) définie à la revendication 2 et Y représente un anion, tel que C104 ", BF4 ", PF5 " .11) Use according to claim 1, characterized in that the diphosphino-metallic complex corresponds to the following formula (IX): M (L) Y 2 (IX) in which M and L have the same meaning as in the formula (II) defined in claim 2 and Y represents an anion, such as C10 4 " , BF 4 " , PF 5 " .
12) Utilisation selon la revendication 1, caractérisée en ce que le complexe diphosphino-métallique répond à la formule (X) suivante : M(L)2Y (X) dans laquelle M et L ont la même signification que dans la formule (II) définie à la revendication 2 et Y représente un anion, tel que C104 _, BF4 ", PFε ".12) Use according to claim 1, characterized in that the diphosphino-metallic complex corresponds to the following formula (X): M (L) 2 Y (X) in which M and L have the same meaning as in formula (II ) defined in claim 2 and Y represents an anion, such as C10 4 _ , BF 4 " , PF ε " .
13) Un complexe diphosphino-métallique de formules (II), (III), (V), (VI), (VII), (VIII), (IX) ou (X), définies à l'une des revendications 2 à 12.13) A diphosphino-metallic complex of formulas (II), (III), (V), (VI), (VII), (VIII), (IX) or (X), defined in one of claims 2 to 12.
14 ) Utilisation d ' un complexe diphosphino - métallique selon la revendication 13 comme catalyseur dans un procédé de catalyse asymétrique .14) Use of a diphosphino-metallic complex according to claim 13 as catalyst in an asymmetric catalysis process.
15 ) Utilisation selon la revendication 14 , caractérisé en ce que le procédé de catalyse asymétrique est un procédé d' isomerisation asymétrique .15) Use according to claim 14, characterized in that the asymmetric catalysis process is an asymmetric isomerization process.
16 ) Util isation selon la revendication 14 , caractérisé en ce que le procédé de catalyse asymétrique est un procédé d' hydrogénation asymétrique .16) Utilization according to claim 14, characterized in that the asymmetric catalysis process is an asymmetric hydrogenation process.
17 ) Uti lisation d ' un complexe diphosphino- métallique selon la revendication 13 comme catalyseur dans un procédé d ' hydrogénation asymétrique de compos és insaturés porteurs de groupements fonctionnels de formule (XVI ) suivante :
17) Use of a diphosphino-metallic complex according to claim 13 as catalyst in a process for asymmetric hydrogenation of unsaturated compounds carrying functional groups of formula (XVI) below:
dans laquelle :in which :
A et B, sont différents et choisis parmi un groupement alkyle en C1_5 , un groupement aryle, un groupement hydroxycarbonyle en Cx_η , un groupement alkoxycarbonyle en Cλ_7 , un groupement aryloxycarbonyle en Cx w , un groupement alogenoalkyle en Cx_7 , un groupement hétéroaryle, un groupement cycloalkyle saturé ou non, Lesdits groupements Alkyle, aryle, cycloalkyle comprenant éventuellement un ou plusieurs substituants choisis parmi un halogène comme le chlore, le fluor, le brome, un groupe -N02, un alkyl en Cx_5 , un alkoxy en Cx_5 , un cycloalkyle en C±_7 fusionné ou non , un groupe aryle, fusionné ou non, éventuellement substitué par un halogène, un alkyl en Cx^5 , un alkoxy en C^ , lesdits groupements alkyle, cycloalkyl, aryl comprenant éventuellement un ou plusieurs heteroatomes tels que O, N ou Si,A and B are different and chosen from a C 1 _ 5 alkyl group, an aryl group, a C x _ η hydroxycarbonyl group, a C λ _ 7 alkoxycarbonyl group, a C xw aryloxycarbonyl group, an alogenoalkyl group in C x _ 7 , a heteroaryl group, a saturated or unsaturated cycloalkyl group, said alkyl, aryl or cycloalkyl groups optionally comprising one or more substituents chosen from a halogen such as chlorine, fluorine, bromine, a group -N0 2 , alkyl C x _ 5 alkoxy C x _ 5 cycloalkyl C ± _ 7 merged or not, an aryl group, fused or unsaturated, optionally substituted by halogen, alkyl C x ^ 5 a C ^ alkoxy, said alkyl, cycloalkyl or aryl groups optionally comprising one or more heteroatoms such as O, N or Si,
Ou encore A et B forment ensemble un groupement alkyle substituée en C2_6, un groupement cycloalkyle en C3_9 saturé ou non, un groupement aryle en C5_10, lesdits groupements étant éventuellement substitués par un alkyle en Cχ.5, un halogène, un hydroxy, un alkoxy en C1_5, un amino tel que NH2, NHR4, N(R4)2, un sulfino, un sulfonyle, où R4 représente un alkyle, un alkoxy ou un alkylcarbonyle, lesdits groupements alkyle, cycloalkyle, aryle comprennant éventuellement un ou plusieurs hétéroatome tel que O, N, S, Si ;Or A and B together form a substituted C 2 _ 6 alkyl group, a saturated or unsaturated C 3 _ 9 cycloalkyl group, a C 5 _ 10 aryl group, said groups being optionally substituted by a Cχ alkyl. 5, halogen, hydroxy, alkoxy, C 1 _ 5, amino such as NH 2, NHR 4, N (R 4) 2, sulfino, sulfonyl, wherein R 4 represents alkyl, alkoxy or alkylcarbonyl, said alkyl, cycloalkyl or aryl groups optionally comprising one or more heteroatoms such as O, N, S, Si;
Q représente un oxygène, un groupe -NR16, -NOR16 ou -C(R16)2, où R16 est choisi parmi un alkyl en Cx-.5, un groupement aryl, un groupement hétéroaryle substitué par un alkyle en C^ .
18) Procédé d'hydrogénation asymétrique d'un composé de formule (XVI) définie dans la revendication 17, caractérisée en ce qu'il comprend le traitement dudit composé de formule (XVI) , dans un solvant approprié, en présence d'un complexe selon la revendication 13, en tant que catalyseur.Q represents an oxygen, a group -NR16, -NOR16 or -C (R16) 2 , where R16 is chosen from a C x- alkyl. 5 , an aryl group, a heteroaryl group substituted by a C 1 alkyl. 18) A process for asymmetric hydrogenation of a compound of formula (XVI) defined in claim 17, characterized in that it comprises the treatment of said compound of formula (XVI), in an appropriate solvent, in the presence of a complex according to claim 13, as a catalyst.
19) Procédé selon la revendication 18, caractérisé en ce que les conditions opératoires sont les suivantes :19) Method according to claim 18, characterized in that the operating conditions are the following:
- Une température comprise entre 0 et +150 °C .- A temperature between 0 and +150 ° C.
- Une pression d'hydrogène entre 1 et 100 bars.- Hydrogen pressure between 1 and 100 bars.
- Une quantité de catalyseur par rapport à la quantité de composé de formule (XVI) comprise entre- An amount of catalyst relative to the amount of compound of formula (XVI) between
1/50000 et 1/10, de préférence comprise 10/10000 et 1/10, tout préférentiellement 10/100 et 1/10.1/50000 and 1/10, preferably 10/10000 and 1/10, very preferably 10/100 and 1/10.
20) Procédé selon l'une des revendications 19 ou 18, caractérisé en ce que la durée d'hydrogénation est supérieure ou égale à 1 heure .20) Method according to one of claims 19 or 18, characterized in that the hydrogenation time is greater than or equal to 1 hour.
21) Procédé selon l'une des revendications 18 à 20, caractérisé en ce que la concentration du composé de formule (XVI) dans le solvant est comprise entre 0,1 et 2 moles/litre.
21) Method according to one of claims 18 to 20, characterized in that the concentration of the compound of formula (XVI) in the solvent is between 0.1 and 2 moles / liter.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0010269A FR2812638B1 (en) | 2000-08-03 | 2000-08-03 | USE OF CHIRAL DIPHOSPHINES AS OPTICALLY ACTIVE LIGANDS FOR THE PREPARATION OF DIPHOSPHINO-METALLIC COMPLEXES, THE COMPLEXES OBTAINED THEREBY AND THE ASYMMETRIC CATALYSIS PROCESSES USING THE SAME |
FR0010269 | 2000-08-03 | ||
PCT/FR2001/002550 WO2002012253A1 (en) | 2000-08-03 | 2001-08-03 | Use of chiral diphosphines as optically active ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1305324A1 true EP1305324A1 (en) | 2003-05-02 |
Family
ID=8853276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01960868A Withdrawn EP1305324A1 (en) | 2000-08-03 | 2001-08-03 | Use of chiral diphosphines as optically active ligands |
Country Status (10)
Country | Link |
---|---|
US (1) | US6794525B2 (en) |
EP (1) | EP1305324A1 (en) |
JP (1) | JP2004505985A (en) |
CN (1) | CN1468248A (en) |
AU (1) | AU2001282264A1 (en) |
BR (1) | BR0112970A (en) |
CA (1) | CA2417836A1 (en) |
FR (1) | FR2812638B1 (en) |
IL (1) | IL154263A0 (en) |
WO (1) | WO2002012253A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2401864B (en) * | 2003-05-21 | 2007-11-14 | Phoenix Chemicals Ltd | Process and catalytic composition |
JP5038392B2 (en) * | 2006-04-03 | 2012-10-03 | エフ.ホフマン−ラ ロシュ アーゲー | Process for the preparation of enantiomerically enriched cyclic β-aryl or heteroaryl carboxylic acids |
SG172217A1 (en) | 2008-12-16 | 2011-07-28 | Hoffmann La Roche | Process for the preparation of pyrollidine-3-carboxylic acids |
FR2952638A1 (en) | 2009-11-17 | 2011-05-20 | Univ Strasbourg | PROCESS FOR THE DOUBLE OR TRIPLE CATALYTIC PHOSPHINATION OF DI, TRI OR TETRAHALOBIARYL COMPOUNDS, INTERMEDIATES EMPLOYED, COMPOUNDS OBTAINED AND USES THEREOF |
CN103145557B (en) * | 2013-03-27 | 2015-06-03 | 石家庄手性化学有限公司 | Preparation method of S-4-chlorine-3-hydroxy butyric acid ethyl ester with optical purity |
CN108690074A (en) * | 2018-05-15 | 2018-10-23 | 东华大学 | A kind of double phosphine chipal compounds and preparation method thereof having phosphorus central chirality and axial chiral binaphthyl concurrently |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993015089A1 (en) * | 1992-01-31 | 1993-08-05 | F. Hoffmann-La Roche Ag | Diphosphine ligands |
WO1993015091A1 (en) * | 1992-01-31 | 1993-08-05 | F. Hoffmann-La Roche Ag | Diphosphine ligands |
ES2130321T3 (en) * | 1993-10-08 | 1999-07-01 | Hoffmann La Roche | OPTICALLY ACTIVE PHOSPHORUS COMPOUNDS. |
CA2290009A1 (en) * | 1998-11-19 | 2000-05-19 | Rhony Niklaus Aufdenblatten | Chiral diphenyldiphosphines and d-8 metal complexes thereof |
JP4947866B2 (en) * | 1999-09-20 | 2012-06-06 | ザ ペン ステイト リサーチ ファンデーション | Chiral phosphines, their transition metal complexes and their use in asymmetric reactions |
-
2000
- 2000-08-03 FR FR0010269A patent/FR2812638B1/en not_active Expired - Fee Related
-
2001
- 2001-08-03 CA CA002417836A patent/CA2417836A1/en not_active Abandoned
- 2001-08-03 CN CNA018167381A patent/CN1468248A/en active Pending
- 2001-08-03 BR BR0112970-8A patent/BR0112970A/en not_active IP Right Cessation
- 2001-08-03 EP EP01960868A patent/EP1305324A1/en not_active Withdrawn
- 2001-08-03 AU AU2001282264A patent/AU2001282264A1/en not_active Abandoned
- 2001-08-03 IL IL15426301A patent/IL154263A0/en unknown
- 2001-08-03 JP JP2002518228A patent/JP2004505985A/en active Pending
- 2001-08-03 WO PCT/FR2001/002550 patent/WO2002012253A1/en not_active Application Discontinuation
-
2003
- 2003-01-31 US US10/356,233 patent/US6794525B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO0212253A1 * |
Also Published As
Publication number | Publication date |
---|---|
BR0112970A (en) | 2003-06-24 |
US20030195369A1 (en) | 2003-10-16 |
IL154263A0 (en) | 2003-09-17 |
AU2001282264A1 (en) | 2002-02-18 |
US6794525B2 (en) | 2004-09-21 |
WO2002012253A1 (en) | 2002-02-14 |
FR2812638B1 (en) | 2003-04-25 |
CA2417836A1 (en) | 2002-02-14 |
FR2812638A1 (en) | 2002-02-08 |
JP2004505985A (en) | 2004-02-26 |
CN1468248A (en) | 2004-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2909382A1 (en) | RUTHENIUM-BASED CATALYTIC COMPLEXES AND THE USE OF SUCH COMPLEXES FOR OLEFIN METATHESIS | |
EP0748326B1 (en) | Optically active diphosphines and method for preparing same by resolution of the racemic mixture | |
EP1899358A2 (en) | Novel p-chiral functionalised arylphosphines and derivatives, the preparation and use thereof for asymmetrical catalysis | |
FR2830254A1 (en) | NEW DIPHOSPHINS, THEIR COMPLEXES WITH TRANSITION METALS AND THEIR USE IN ASYMMETRICAL SYNTHESIS | |
EP1305324A1 (en) | Use of chiral diphosphines as optically active ligands | |
WO2000049028A1 (en) | Method for preparing chiral diphosphines | |
EP0912467B1 (en) | Asymmetric hydrogenation method of a ketonic compound and derivative | |
EP2607353B1 (en) | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | |
CA1313196C (en) | Process for the preparation of insaturated alcohols | |
WO2008135386A1 (en) | Chiral ligands of the n-heterocyclic carbene type for asymmetrical catalysis | |
CA2429252A1 (en) | Chiral diphosphines and their metal complexes | |
EP1268496A1 (en) | Water soluble chiral diphosphines | |
EP0968220A1 (en) | 6,6'-bis-(1-phosphanorbornadiene) diphosphines | |
FR2796951A1 (en) | PHOSPHINE / PALLADIUM COMPLEXES, USEFUL AS CATALYSTS, IN PARTICULAR FOR THE ARYLATION OF OLEFINS | |
FR2849036A1 (en) | New 5,5'-disubstituted 2,2'-diphosphino-1,1'-binaphthyl derivatives, useful as ligands in transition metal complex catalysts for asymmetric reactions such as hydrogenation | |
WO2012049424A2 (en) | Method for synthesizing phosphine | |
WO2023247697A1 (en) | Novel iron-based compounds, processes for the preparation thereof, and use thereof as catalysts | |
EP2200986B1 (en) | Chiral tridentate compounds, corresponding organometal complexes, method for preparing same and use of said compounds and complexes as ligands in asymmetrical catalysis | |
FR2810666A1 (en) | New beta amino alkyl-phosphine, -phosphite, -phosphonite and -phosphinite chiral ligands, the transition metal complexes of which are useful as asymmetric catalysts | |
WO2000027854A1 (en) | Phosphine-phosphite type derivatives | |
FR2849037A1 (en) | New 4,4'-disubstituted 2,2'-diphosphino-1,1'-binaphthyl derivatives, useful as ligands in transition metal complex catalysts for asymmetric reactions such as hydrogenation | |
WO2000047590A1 (en) | Tris[(1h,1h, 2h,2h-perfluoroalkyl) aryl]phosphites and catalytic uses thereof | |
FR2875500A1 (en) | MACROCYCLIC CHIRAL COMPLEXES USEFUL AS CATALYSTS | |
JPS5850207B2 (en) | Hydrogenation method | |
FR2734823A1 (en) | Optically active di:phosphine(s) prepd. from the racemic mixt. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030203 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ROUSSIASSE, SONIA Inventor name: LABOUE, BLANDINE Inventor name: BULLIARD, MICHEL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20060329 |